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ABSTRACT 
 Respiratory syncytial virus (RSV) and other respiratory viruses are known for their 
implications in asthma exacerbation and development; many population-wide epidemiological 
studies indicate this correlation. Among children less than two years old, 99% have experienced 
an RSV infection, and about 36% of those children have also had a second infection. Due to this 
high frequency of RSV infections, infants also have a high chance of exposure to benign 
particulates before, during, and after a viral infection has peaked. There are many mouse models 
used to deduce immunological pathways leading to asthma development and exacerbation. I 
developed a model in mice where a natural route of allergen entry was utilized with another 
timeline of viral infection and allergen exposure. In this model, allergen exposure occurs during 
viral infection and after clearance; this realistically replicates a situation in children who are 
constantly exposed to benign allergens irrespective of their viral clearance status.  
 My model shows that if initial exposure occurs during a pneumonia virus of mice (PVM) 
infection, a secondary immune response towards cockroach allergen (CRA) is modified and 
becomes more inflammatory than if CRA exposure happens without any viral infection. Utilizing 
this model, we observed an increase in mucin mRNA (Gob5 and Muc5AC), as well as induction 
of IFN-γ, IL-4, and IL-10 mRNA and their corresponding cytokine proteins. Furthermore, we 
observed an increase in the influx of macrophages and dendritic cells in the lungs, indicating the 
presence of an inflammatory response towards CRA. Neutrophil and eosinophil influx within the 
bronchoalveolar lavage fluid and the lung tissue changed when mice were exposed to CRA 
during acute viral infection. This influx occurred despite the second exposure taking place after 
viral clearance and suggested a Th-2 skewed inflammatory response. IDO (indoleamine-2,3-
dioxygenase)-1 expression was also enhanced towards CRA when the first exposure occurred 
during an underlying PVM infection. Thus, the overall response was stronger towards CRA than 
what CRA induced without an underlying PVM infection. This stronger response may correlate 
to the enhanced IDO-1 expression previously observed. Therefore, our data indicate that 
exposure to benign allergens during a respiratory infection can modify the response due to 
infection and produce a Th-2 type inflammatory response without additional eosinophil influx.   
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1 INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Human Respiratory Syncytial Virus (RSV) Within the Human Population 
 
1.1.1 RSV disease burden and epidemiology  
RSV (Human Orthopneumovirus) is a member of the Pneumoviridae family (1). It is a 
single-stranded negative-sense RNA virus that infects the epithelial cells of the upper airway. 
Once there, RSV may also travel to the lower respiratory tract (2). It usually causes a common 
cold within immunocompetent individuals; within immunocompromised persons, such as infants 
and the elderly, RSV infection can develop into bronchiolitis and eventually lead to 
hospitalization and death (1, 3). RSV is transmitted through large droplets and fomites and is 
stable for hours in the environment (4), and close contact (person to person or person to fomites) 
is necessary for transmission (4).  
There is no vaccine against this disease, but there is an antibody called Palivizumab that 
is used preventatively for infants classified as high-risk according to the World Health 
Organization (WHO) (5). Once infected, the administration of ribavirin and supplemental 
oxygen have been used as therapies (6).  
Severe bronchiolitis due to RSV can produce wheezing symptoms in 40-50% of 
hospitalized infants, (7) and can exacerbate asthmatic symptoms (5, 8). Due to these factors, 
severe RSV bronchiolitis is now considered a risk factor for asthma development if contracted 
during infancy (5, 8, 9). Therefore, extensive research is necessary to understand the 
pathogenesis of RSV infection, and how it may lead to severe bronchiolitis and subsequent 
asthma development.  
 
1.1.2 Animal models of RSV 
The viruses within the Pneumoviridae family are quite species-specific, meaning that 
animal models of human RSV are somewhat inaccurate. A classic mouse model is the Balb/c 
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strain, though the viral titer needed for infection is quite high (5 x 105 pfu/mouse). Even so, the 
mice can clear the infection with some clinical symptoms observed (10). This clearance, with 
little to no symptoms, is also seen in RSV infection of Balb/c neonates, which does not replicate 
a human neonatal RSV infection (10). 
A cotton rat model that replicates human RSV infections more accurately still has its 
drawbacks since cotton rats seem to be better able to combat RSV infection. Cotton rats also 
have slightly different cellular markers and subsequent functions when compared to the human 
immune system (similar to the significant drawbacks of the mouse model). Also, there is a 
smaller array of reagents for measuring cotton rat immunological responses. 
Other animal models of RSV include sheep, rabbits, and guinea pigs (10), but they all 
have their advantages and disadvantages. Despite being more easily manageable, the smaller 
animals do not always accurately replicate a response to RSV infection similar to the general 
human population. Again, this can be partially due to vital immunogenetic differences between 
the smaller host animals and humans (11). Apart from the mouse model, there are fewer research 
tools developed for the other smaller animal models. The most significant disadvantage is, of 
course, that these viruses are species-specific. As such, a human study was performed on adults 
inoculated with RSV, and the disease symptoms were not representative of human neonatal 
disease (11). This difference in RSV infection between the two age groups suggests that age also 
plays a critical factor within these models. 
Other models using the animal RSV viruses with their corresponding hosts are used to 
overcome the somewhat inaccurate results from RSV animal models. There are two well-known 
models of this kind: the bovine respiratory syncytial virus (bRSV) cattle model and the 
pneumonia virus of mice (PVM) mouse model. The bRSV virus causes a natural respiratory 
infection in cattle. The respiratory tract infection within younger calves causes severe bronchitis, 
while older cattle have a less severe form of the infection. These differences replicate different 
infection severities between human adults and infants with RSV (6). Likewise, if bRSV is 
processed using the same protocol as the formalin-inactivated-RSV/alum vaccine, young calves 
show similar enhanced disease seen in the infants who were administered the RSV vaccine (12). 
These critical similarities imply that the bRSV cattle model may be best for understanding RSV 
infections within infants. The downside to this model is that large animals are more cumbersome, 
challenging to handle, and expensive due to their size and housekeeping needs (6). 
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Another useful model is the RSV chimpanzee model. RSV was first isolated from 
chimpanzees with an upper respiratory tract infection (URTI), that was called chimpanzee coryza 
agent (CCA). Soon after, CCA was identified as a human-born virus (6). Most studies using this 
RSV chimpanzee model have documented coughing, sneezing, and rhinorrhea. One study 
documented a lower respiratory tract infection (LRTI) with bronchopneumonia in a 14-month-
old chimpanzee (6). Therefore, this model can replicate the URTI caused by human RSV, which 
shares the same set of symptoms documented in most healthy adults (5). The use of this model 
for RSV-induced LRTIs within infants may not be as accurate, assuming that most studies with 
chimpanzees are utilizing adults instead of infants. The case of LRTI within a young chimpanzee 
suggests that younger hosts may have an RSV infection that replicates what is seen in human 
infants. The use of chimpanzees for RSV studies has been vital, although the high cost, and 
unique housekeeping needs limit their use for general RSV vaccine trials (6). 
 
1.1.3 RSV pathology 
RSV enters the upper airways of its host and replicates in the nasopharynx before 
traversing lower and infecting the epithelial layer of the lungs (6). Here, innate immunity is 
triggered, and an immune response develops that leads to clearance of the virus (13). 
Epidemiological studies of RSV have specified differences in disease severity between adults 
and infants, and these infants seem to be biased towards developing a Th-2 response (13). There 
is evidence that while the virus is still cleared, the cytokines attributed to the Th-2 response may 
cause long-lasting modifications to the lung tissue (14) and can lead to wheezing (15). 
Many biomarkers have been examined to discern which infants are predisposed to 
developing severe disease and discover correlations between disease and wheezing (1, 14-17). In 
the Moreno-Solis et al. study, infants with bronchiolitis who needed oxygen supplementation due 
to the severity of their disease were distinguished from those with less severe bronchiolitis by 
increased IL-6 and MIP-1β within the nasopharyngeal aspirate (16). Generally, infants with RSV 
bronchiolitis showed increased IL-4 and IFN-γ protein expression as a mixed response with more 
IFN-γ than IL-4 protein produced. In addition, IL-6, IL-8, IL-10, MIP-1α, MIP-1β, and TNF-α 
proteins were all found in the nasopharyngeal aspirates. Infants with RSV bronchiolitis also 
showed increased IL-8, MIP-1α, and MIP-1β in the plasma (16). These plasma chemokines are 
indicative of the systemic need for neutrophil recruitment and other leukocytes to the lungs.  
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Both Shinohara et al. and Okamoto et al. performed studies focusing on eosinophilia and 
wheezing in infants with respiratory diseases (15, 17). Both studies compared nasal secretions 
and blood samples and correlated them with environmental factors such as family history and 
pre-existing allergies. While each study focused on different aspects and severity of the disease, 
both groups suggested that eosinophilia was commonly observed in both URTIs and LRTIs. 
They also indicated that factors of eosinophilia during LRTIs were correlated to allergy factors; 
eosinophilia in URTIs did not show this same correlation. 
Shinohara et al. used a cohort of 35 children (mixed sexes) diagnosed with rhinorrhea 
aged 6-33 months (15). In this study, eosinophilia did not correlate with any environmental 
factors such as pre-existing allergies, family history, age, nor sex. Results from the blood 
samples taken at the end of the study identified no correlation between nasal eosinophilia, factors 
such as total IgE, and neither percent, nor quantity, of eosinophils seen at the start of the study. 
However, there was a correlation between wheezing and eosinophilia seen at the beginning of 
the study and wheezing 2 months after entry of the participants. By 12 months after entry, the 
patients no longer exhibited any correlation between factors measured at the beginning of the 
study and wheezing at 12 months (15). From this study, it can be determined that a respiratory 
tract infection localized to the URT does not seem to result in long-lasting wheezing. Also, 
eosinophilia within the nasal secretions during the infection did not correlate with either family 
history or laboratory findings. These lack of correlations suggests that eosinophilia is a typical 
response towards a URTI, and not indicative of long-lasting wheezing nor changes within the 
lung environment that may make a systemic impact on the children. Even so, a follow-up study 
measuring the forced expiration of volume in 1 second (FEV1) of the lungs, nasal secretions, and 
blood samples during and between later respiratory illnesses may be beneficial in understanding 
if there are any long-lasting, but more silent, changes within their lungs. 
In contrast, Okamoto et al. compared and contrasted the primary eosinophil protein 
eosinophilic cation protein (ECP) within infants less than 2 years old who were hospitalized for 
LRTs, including RSV infections (17). These infants were separated based on sex, pre-existing 
allergies or a serum IgE titer of over 200 U/mL, whether their infection was caused by RSV, 
whether they had wheezing, and whether they were predisposed to allergies due to family 
history. All samples were taken at the time of hospitalization, declared the infectious phase. It 
was shown that a significant increase in ECP within the nasal secretions, but not the plasma, 
5 
 
correlated with wheezing within the infants. When ECP was compared between children with 
RSV infections and those with other LRTIs, ECP was also significantly increased in those with 
the RSV infection. Again, this was seen in the nasal secretions, but not replicated within the 
plasma. Even so, there was no correlation between nasal or plasma ECP in the infants regardless 
of predispositions to asthma and allergies. Some samples were also taken one day before 
discharge, and once respiratory symptoms had resolved, which was designated the recovery 
phase. Neither nasal secretions nor plasma ECP levels showed significant differences between 
the infectious and recovery phases. However, there were correlations between the infectious and 
recovery phases and neutrophil and eosinophil counts when compared to ECP levels. There was 
also a correlation between ECP levels at the recovery phase and pre-existing allergy factors (17). 
All of these correlations suggest that while the presence of ECP seems to be a general response 
towards LRTIs, RSV induces eosinophilia and increases ECP concentrations in comparison to 
other viruses. The ECP is always localized to the nasal secretions, and these levels do not 
significantly decrease one day after symptoms resolve. The levels of ECP during the recovery 
phase did correlate to pre-existing allergy factors. Since traditional allergies are known to be 
eosinophilic responses towards food or air-born particles, this is reasonable to expect. In 
addition, it is not surprising that there are no noticeable differences in ECP levels between the 
infectious and recovery phases since mouse models have indicated that it takes weeks after 
symptoms have diminished for the lung environment to return to basal levels (18).  
While these two studies on infants identified eosinophilic infiltration during RSV 
infection, Bertrand et al. looked at the cytokine and chemokine profiles from both 
nasopharyngeal aspirates and bronchoalveolar lavage (BAL) fluid of 14 infants (aged 0-9 
months) with severe RSV-induced bronchiolitis and 5 control infants ( aged 1-6 months) (19). In 
follow-ups occurring for 3 years after the study, it was concluded that wheezing, asthma, or the 
need for corticosteroid therapies were more likely to occur within the infants who had RSV-
bronchiolitis during this study. According to the study, BAL fluid sampled for select proteins 
described significant increases in IL-4, IL-10, IL-1β, IL-6, TNF-β, IL-12p40, CCL2, CCL3, and 
CXCL8 (IL-8) within the infants who had severe RSV-induced bronchiolitis relative to the 
control group of infants. Additionally, CCL-11 (eotaxin) and IL-12p70 levels were decreased in 
these same infants with RSV bronchiolitis. Neither IFN-γ nor IL-17 protein levels were found to 
change between the two cohorts. The nasopharyngeal aspirates were used for qPCR analysis and 
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contained significantly decreased IL-1β, IL-6, and CCL2 mRNA levels. During the last follow-
up, infants who developed asthma were found to have increased CCL11, IL-5, TNF-β, IL-12p40, 
and IL-12p70 within their BAL fluid during the previous RSV bronchiolitis. Also, those infants 
whose parents were atopic (one or both parents diagnosed with rhinitis or atopic asthma), had 
significantly higher levels of IL-33 mRNA expression (19). Although no cell populations were 
identified in this study, the overall decrease of eotaxin and increase of CCL2, CCL3, and IL-8 
suggests suppression of eosinophils, and recruitment of leukocytes, such as neutrophils. Even so, 
there was a predominant Th-2 and pro-inflammatory response in these infants with bronchiolitis. 
Thus, the lung environment was Th-2 dominant with suspected neutrophilia and suppressed 
eosinophilia. Interestingly, those infants who developed asthma within the 3-year follow-up had 
a slight, but significant, increase in proteins that would suggest eosinophilia. Therefore, infants 
that may have a slightly mixed neutrophilia and eosinophilia response may be more prone to 
developing asthma as opposed to just neutrophilia, as seen here, or eosinophilia, as seen 
previously (15, 17). 
In an FVB/n mouse model from Sun et al. production of CXCL1, CCL2, MIP-1α (CCL3) 
protein and expression of IP-10 (CXCL10), and MIP-2 (CXCL2)  mRNA were induced within 
24 hrs of infection (8). In addition to those chemokines, IL-1β, IL-6, IL-12, and IFN-α protein 
production were also induced at 24 hrs (8). These protein increases led to a pro-inflammatory 
response with general leukocyte and neutrophil recruitment, which was necessary for viral 
clearance. The adaptive immune response mounted by day 8 and was specific for RSV virions 
(8). Researchers observed increases in IFN-γ, IL-13, IL-4, Muc5AC, and Gob5 mRNA 
expression, and an increase in IL-12 protein production. This study also showed a nominal 
increase of neutrophils at days 9 and 14, but no eosinophils were detected. Sun et al. were 
studying the effects of IL-10 on early and late RSV infection; therefore mice were transgenic to 
express human IL-10 (hIL-10), but mouse IL-10 (mIL-10) expression was not modified. As such, 
Sun et al. identified the complex nature of IL-10 functioning as both an immunosuppressive and 
proinflammatory cytokine. IL-10 was identified as suppressing the pro-inflammatory Th-2 
responses because anti-IL-10 serum, administered at the time of infection, resulted in 
significantly increased IL-13, IL-4, IL-5, Muc5AC, and Gob5 mRNA levels (8). Therefore, 24 
hrs after RSV infection, there was a pro-inflammatory response that was more neutrophilic. This 
response led to a mixed Th-1/Th-2 response by day 8 with high mucus mRNA production. 
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Neutrophilia was still detectable at days 9 and 14 showing this long-lasting effect soon after viral 
clearance generally occurs. Other results within the same study discovered that overexpression of 
hIL-10, both before infection and during peak viral infection, still increased Muc5AC and Gob5 
mRNA levels. This contradiction could be due to IL-10 being overexpressed instead of a gradual 
increase over the course of infection as mediated by endogenous IL-10 mRNA levels.  
Mukherjee et al. performed an RSV study explicitly looking at IL-17A during infection 
(20). First, infants with and without RSV infection (hospitalized with mechanical ventilation) 
had tracheal aspirates taken to determine IL-17 protein concentrations. These samples showed a 
significant increase in IL-17 concentrations when infants had RSV infections compared to those 
that did not have an RSV infection. They then used Balb/c mice and RSV strain A (line 19) to 
show that IL-17 was induced by RSV infection with CD4+ T-cells producing the most IL-17A 
within the lungs compared to both NK cells and γδ T-cells. Day 8 was shown to be the peak of 
IL-17A production and was used to determine effects of anti-IL-17A antibodies or in IL-17A KO 
mice with RSV infection. Both suppression and KO of IL-17A showed a significant decrease in 
Muc5AC and Gob5 mRNA levels. In addition, this RSV infection caused both neutrophilia and 
eosinophilia, but suppression of IL-17A decreased neutrophilia and seemed to ablate eosinophilia 
within the BAL fluid. This suppression did not interfere with either macrophage or lymphocyte 
influx. 
Additionally, the suppression of IL-17A decreased KC mRNA levels, which would 
explain the decrease in neutrophilia within the BAL fluid. No other chemokines measured were 
affected by the anti-IL-17A antibodies. They also showed that this RSV infection stimulated a 
mixed Th-1/Th-2 response with similar levels of IL-4 and IFN-γ mRNA expression, but a 
slightly higher IFN-γ than IL-4 protein production. IL-17A suppression did not interfere with 
these cytokines. 
Additionally, IL-5 (essential for eosinophils) and IL-13 (Th-2 cytokine known to induce 
mucus production within goblet cells) were also induced by RSV, but not through IL-17A 
induction. They then looked at CD8+ T-cells and found that there was a higher percentage of 
these effector cells expressing IL-17RA, the receptor for IL-17A. Suppression of IL-17A not 
only increased the number of CD8+ T-cells specific for the RSV by staining the RSV-specific 
immunodominant T-cell receptor, but also increased the overall quantity of CD4+ and CD8+ T-
cells. These CD8+ T-cells were more likely to express IFN-γ, the transcription factors t-bet and 
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eomesodermin (eomes), and the apoptosis-inducing factor granzyme B.  
Therefore, RSV pathology is incredibly complex, with many different factors playing a 
role in the immune-mediated infection. Genetic backgrounds within humans could influence 
these factors, and these manipulations could lead to the development of the different asthmatic 
phenotypes we are witnessing today. 
 
1.2 Pneumonia Virus of Mice (PVM) in Mice as an RSV Model 
 
1.2.1 Disease 
Pneumonia virus of mice (PVM) is a pneumovirus that causes an immune-mediated 
disease in mice that is similar to the neonatal RSV infection (21). The mice show significant 
weight loss, a lack of grooming, and limited mobility while they are combating the disease (22). 
It was also found that all PVM proteins have homologues within RSV (21), which display 
homologous functions. Susceptibility to infection is based on the strain of mouse used, which 
corresponds to the immune response mounted by each strain (21). Overall, the Balb/c mouse is 
more susceptible to PVM infection than the C57Bl/6 mouse (21, 23). There are also two different 
strains of PVM virus (21). The first strain is PVM-15. A lethal dose of this virus is 3000 
pfu/mouse, and this strain induces a neutrophilic infection within mouse lung tissue (21). The 
second strain of PVM (PVM-J3666) is highly infectious in comparison and induces an 
eosinophilic response within susceptible strains of mice. Despite their differences in cellular 
influx, both viral strains are commonly-used models for RSV infection (21, 24). 
 
1.2.2 Innate immunity 
According to Dyer et al. (25), PVM activates TLR7 (a receptor that recognizes single-
stranded RNA) since mice lacking this receptor did not recruit neutrophils and NK cells; the 
induction of interferons and viral clearance was also delayed. Additionally, macrophages are 
necessary for the clearance of virus particles, but their depletion resulted in a larger influx of NK 
cells and a corresponding increase of IFN-γ, which still led to viral clearance. The implication of 
macrophages and NK cells along with IFN-γ induction suggests the development of a Th-1 
biased adaptive immune response. 
Domachowske et al. compared PVM-15 and PVM-J3666 within C57Bl/6 mice and found 
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differences in the immunology response between the two viruses (26). The group used 200 pfu of 
each virus, which is a known lethal dose of PVM-J3666 and a sub-lethal dose of PVM-15. Mice 
inoculated with PVM-J3666 all succumbed to the infection by day 7 p.i.; PVM-15 infected mice 
became quite ill with ruffled fur and lack of grooming between days 4-6 p.i., but recovered from 
their infections and were virus-free by day 10. Histological samples from the PVM-15 infected 
mice on day 4 p.i. showed almost no airway inflammation or structural changes. There was one 
mouse in this group that developed slightly more severe symptoms and had more structural 
changes and some leukocyte infiltration within its lungs. Contrastingly, the mice inoculated with 
PVM-J3666 had severe structural changes and increased neutrophil numbers within their lungs 
on day 4 p.i. 
Furthermore, analysis of the leukocytes within the lung infiltrates on days 1, 2, 3, and 4 
p.i. revealed little change in total cell numbers within the PVM-15 group; the lungs of these mice 
contained a balance of both granulocytes (neutrophils and eosinophils) and lymphocytes on day 
1 p.i. This balance shifted to a large influx of granulocytes coupled with a small efflux of the 
lymphocytes. By day 1, the mice inoculated with PVM-J3666 had a larger proportion of 
granulocytes compared to lymphocytes with a similar total cell number when compared to the 
PVM-15 group. The total cell numbers drastically increased and became completely comprised 
of granulocytes, while no lymphocytes were seen within these lungs. MIP-1α (macrophage, 
neutrophil, eosinophil, and lymphocyte chemoattractant) and MCP-1 (monocyte, memory T-cell, 
and dendritic cell chemoattractant) production in the PVM-J3666 infected mice were detected by 
day 2 p.i. and continued to increase in concentration on both days 3 and 4 p.i. However, no 
protein was detected on these same days within the PVM-15 infected mice. PVM-J3666 infected 
lungs responded to the virus with high induction of proinflammatory mRNAs including IFN-β 
and MCP-1 even though there was no induction of either IFN-α or IFN-γ on day 3 p.i. according 
to microarray analysis. PVM-15 infection did not induce any of these same mRNAs except for 
RANTES (an eosinophil chemoattractant) (26). Therefore, the general conclusion of this study 
was that PVM-15 had a non-pathogenic phenotype within C57Bl/6 mice.  
An earlier study also performed by Domachowske et al. in 2000 observed the pathology 
of PVM-J3666 within Balb/c mice (27). At an inoculation of 300 pfu per mouse, the Balb/c mice 
all succumbed to their illness by day 6 p.i. The BAL fluid consisted of about 12% eosinophils 
and 60% neutrophils on day 3 p.i. but it shifted to become less than 5% eosinophils and about 
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80% neutrophils by day 5 p.i. On day 3 p.i., the lung tissue, through microscopic analysis and 
H&E staining, had a predominant eosinophilic influx with some neutrophilic influx. Therefore, 
the early and innate response towards PVM-J366 within BALB/c mice is predominantly 
neutrophilic with some eosinophilic influx within the BAL fluid.  These eosinophils start leaving 
the BAL fluid as the infection continues. At the same early time-point, the lung tissue has a 
predominant eosinophilic influx and lower neutrophilic influx. Eotaxin and RANTES protein 
concentrations (eosinophil chemokines) did not differ during this infection, and IL-5 was not 
detected. MIP-1α protein was detected within the mice at day 3 p.i., and the concentrations 
peaked at day 4 p.i., followed by a decrease at day 5 p.i. (27). Therefore, Domachowske et al. 
concluded that although eotaxin and RANTES were not contributing to this infection, MIP-1α 
may be the eosinophil chemoattractant necessary for the 12% eosinophil influx at day 3 p.i., and 
its decrease may account for the efflux seen on days 4 and 5 p.i.  
However, in 2004, a study performed by Krempl et al. re-evaluated the virulence of 
PVM-15 within Balb/c mice (23). In addition to the Domachowske paper in 2000 (26), a 1995 
paper by Randhawa et al. (28) and one done in 1967 by Harter et al. (29) concluded that PVM-
15 was not as infective in Albino Swiss mice as compared to the PVM-J3666 strain. Krempl et 
al. used a PVM-15 strain from ATCC, which is one of the strains originally isolated by Horsfall 
and Hahn in 1939 (30). They compared this strain with the PVM-J3666 strain in Balb/c mice and 
concluded that mice infected with either viral strains succumbed to their illnesses around the 
same day; these symptoms were dose-dependent in both strains. Genome sequencing revealed 
mutations within the PVM-15 strain used by Domachowske et al. and Randhawa et al. that were 
not seen within the PVM-15 strain used in the Krempl et al. study (23, 28). Additionally, a 
second study by Krempl et al. deduced the dose-dependent lethality of PVM-15 within Balb/c 
mice: 101 pfu is non-lethal, 102 pfu is sub-lethal, and 103 pfu is lethal (31). 
Watkiss et al. compared 30, 300 and 3000 pfu of PVM-15 (ATCC strain) within both 
Balb/c and C57Bl/6 mice and detected both innate and adaptive immune response differences 
between the two mouse strains (21). Balb/c mice inoculated with 30 pfu expressed no significant 
weight loss, though mice given 300 pfu did show significant weight loss, and some succumbed 
to their infections. At 3000 pfu all of the mice showed drastic weight loss and started 
succumbing to their illnesses by day 5 p.i., none survived past day 7 p.i. C57Bl/6 mice 
inoculated with either 30 pfu or 300 pfu did not show significant weight loss and survived until 
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the end of the trial. When inoculated with 3000 pfu, these mice showed significant weight loss, 
and about 25% had succumbed to their illness by day 7 p.i. Therefore, the C57Bl/6 mice were 
more resistant to PVM infection than the Balb/c mice in this study.  
According to this study, a 30 pfu inoculation of PVM-15 (non-lethal dose) within Balb/c 
mice induced mRNA production of IFN-α and some IFN-γ (proinflammatory cytokines), as well 
as CXCL8 (IL-8 – neutrophil chemokine), CXCL10 (IP-10 – effector T-cell chemokine), CCL3 
(MIP-1α) and CCL2 (MCP-1) by day 5 p.i.; none of these mRNAs were induced at day 3 p.i. 
within the Balb/c mice. The C57Bl/6 mice had a similar increase in these cytokines and 
chemokines when inoculated with 3000 pfu, again at day 5 p.i. Additionally, macrophages were 
the most abundant cell population within the BAL fluid at day 3 p.i., but by day 5 p.i. a nominal 
neutrophilic influx was also detected in Balb/c mice. Similar results were found in C57Bl/6 mice 
inoculated with 3000 pfu. At day 5 p.i., there was an increase in chemokines CCL3, CCL2, 
CXCL8, and CXCL10, which also recruit NK cells (21). At day 6 p.i., a substantial population of 
NK cells secreting IFN-γ were detected, but neither CD4+ nor CD8+ T-cells were detected within 
the Balb/c mice. A significantly smaller number of NK cells secreting IFN-γ were found at the 
same time-point in C57Bl/6 mice even though both mice express the same amount of this mRNA 
by day 5 p.i. Watkiss et al. also suggests a connection between IFN-γ and the infiltration of 
neutrophils. A previous study showed IFN-γ-dependent neutrophilic influx using IFN-γ-/- Balb/c 
mice that also over-expressed CCL3 (neutrophilic chemokine). Over-expression of CCL3 did not 
result in neutrophilic influx until recombinant IFN-γ was administered to these mice. This study 
concluded that the innate response within both Balb/c and C57Bl/6 mice includes high 
macrophage infiltration and IFN-γ mRNA induction, which promotes a Th-1 biased adaptive 
immune response (21). 
 
1.2.3 Adaptive immunity 
An adaptive immune response is highly specialized and uses enhanced elimination 
processes that are specific for one pathogen-type (i.e. the adaptive immune cells specific towards 
an influenza virus will not be able to target RSV virions). Additionally, different adaptive 
immune responses are necessary for different types of pathogens. Therefore, the response can be 
either Th-1, Th-2, or Th-17 – biased or sometimes a combination of these responses, depending 
on the different cytokines, chemokines, and cellular populations attracted and produced by the 
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innate immune system within the infected tissue. Typically, Th-17 responses are neutrophil-
biased and mounted towards extracellular fungal and bacterial infections, but are also implicated 
in immunosuppressive responses (32). Th-1 responses are considered cell-mediated and mounted 
to intracellular pathogens (viruses, and some bacteria). Th-2 responses are considered humoral 
and mounted to extracellular pathogens (some bacteria and helminths).  
The Th-1 response is traditionally mounted to intracellular pathogens such as intracellular 
viruses and bacteria. This response is canonically defined as cell-mediated and develops due to 
high IL-12 concentrations produced by M1 macrophages and dendritic cells,  and IFN-γ 
produced by NK cells during the innate response (33). Characteristics of this adaptive response 
include numerous IFN-γ-secreting CD4+ T-cell (Th-1 CD4+ T-cells) and cytotoxic CD8+ T-cell 
populations, coupled with IgG2a production by B-cell populations. IFN-γ induces enhanced 
microbicidal activity within macrophages, which includes secreting TNF-α and IL-12 pro-
inflammatory cytokines. IFN-γ also stimulates IgG2a class-switching in B-cells and, coupled 
with IL-12 from macrophages or dendritic cells, produces IFN-γ-secreting CD4+ T-cells and 
cytotoxic CD8+ T-cells. Naïve CD4+ T-cells are induced to express transcription factor T-bet 
through both IL-12 and IFN-γ signalling. T-bet induces IFN-γ secretion and suppresses GATA3 
induction. Thus the Th-2 skewed response is inhibited, and the T-cells become Th-1 biased and 
secrete IFN-γ. The secreted IFN-γ also stimulates macrophage microbicidal activity and IgG2a 
class-switching in B-cells (34). They are also important in stimulating and maturing CD8+ T-
cells so that their cytotoxic properties are enhanced and specific fore infectious particle. 
Cytotoxic T-cells are important because they can recognize infected host cells that are expressing 
specific pathogen targets and induce apoptosis within these cells, thus interrupting the replication 
cycle of an intracellular pathogen. IFN-γ is also known to suppress both the Th-2 and Th-17 
immune responses. 
Alternatively, the Th-2 response includes Th-2 CD4+ T-cells, M2 macrophages N2 
neutrophils, eosinophils, mast cells, and basophils, as well as IgE class-switching of B-cells, and 
secretion of cytokines such as IL-4, IL-5, IL-13, and IL-25 (34, 35). This response is typically 
mounted in response to extracellular pathogens and helminths that are difficult to clear with a 
Th-1 response. Naïve T-cells transiently express GATA3 (Th-2 CD4+ T-cell transcription 
factor), while IL-2 (a generic cytokine transiently expressed and necessary to sustain activated 
CD4+ T-cells) induces STAT5 activity (36). Both of these transcription factors are necessary for 
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Th-2 T-cell differentiation. Thus, naïve CD4+ T-cells seem able to differentiate into Th-2 T-cells 
without extracellular cytokine stimulus (36). Th-2-cells secrete cytokines such as IL-4, IL-5, IL-
9, IL-10, IL-13, and IL-25 (33). CD4+ T-cell derived IL-4 induces cytotoxic CD8+ T-cells that 
express the GATA3 transcription factor and produce IL-4 and IL-13 cytokines (37, 38). IL-4 
production by Th-2 cells also induces IgE and IgG1 class switching of B-cells. 
Therefore, the induction of IFN-α and IFN-γ mRNA production at day 5 p.i. coupled with 
the influx of macrophages and NK cells in the Watkiss et al. study (21) reportedly led to a Th1-
biased environment. Both mouse strains were sampled at days 14 and 28 p.i. (30 pfu inoculation 
of Balb/c and 300 pfu of C57Bl/6) to observe the adaptive immune response through total and 
neutralizing antibody titers, and PVM specific IFN-γ or IL-5 secreting splenocytes. Neither strain 
produced PVM-specific IgE antibodies, but there was PVM-specific IgA in the lungs and PVM-
specific IgG in the lungs and serum at day 14 p.i. in both Balb/c and C57Bl/6 mice. At day 28 
p.i. the Balb/c mice had increased Ig titers, but the C57Bl/6 mice maintained their titers. Both 
strains also produced virus-neutralizing antibodies, but the C57Bl/6 mice produced a nominal, 
but significant, increase in the antibodies both within the serum and the lung tissue compared to 
the Balb/c mice.  
An ELISPOT assay measuring the IFN-γ or IL-5 producing splenocytes also showed 
differences. Both Balb/c and C57Bl/6 mice developed IFN-γ-producing cells at day 14 p.i. and 
these populations significantly decreased by day 28 p.i. The Balb/c mice had a significantly 
lower number in comparison on day 14 p.i. however, this cell population did not decrease to the 
same extent and thus had a significantly larger amount by day 28 p.i. Only Balb/c mice 
developed IL-5-producing cells at day 28 p.i. although these cells were not detected at day 14 p.i. 
 Overall, Watkiss et al. (21) showed a sustained IFN-γ-producing cell population at day 
28 p.i. in Balb/c mice, higher than the population found in C57Bl/6 mice. This constant cellular 
influx suggests that the response within Balb/c mice is rapid and long-lasting when compared to 
similar responses of the C57Bl/6 mice. Additionally, not only was there a sustained number of 
IFN-γ-producing lymphocytes at this time-point, but there was also a small but increasing 
number of IL-5 producing cells. These cells could be indicative of an eosinophilic-primed 
response because IL-5 is a known eosinophil chemoattractant. Therefore, both Balb/c and 
C57Bl/6 mice develop an initial neutrophilic and Th-1 response for viral clearance, although the 
Balb/c mice develop this response earlier and it decreases less after clearance of a sub-lethal 
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PVM-15 infection while a Th-2 and eosinophilic response also initiate at this time.  
Another study by Frey et al. in 2008 identified a role for CD4+ and CD8+ T-cell -
mediated immunopathology in a C57Bl/6 and PVM-15 infectious mouse model using a dose of 
250 pfu (39). A sub-lethal dose of PVM-15 administered to C57Bl/6 mice resulted in weight loss 
around day 8 p.i.; this coincided with increasing total cell counts within the BAL fluid and a 
decrease in virus. Also during this time, a significant portion of the total BAL fluid cells were 
CD3+ which is the marker for T-cells; more specifically, this group was mostly comprised of 
CD8+ T-cells with a small population of CD4+ T-cells. When comparing TCRβδ-/- and TCRβ-/- 
knock-out mice to wild-type mice, the virus load persisted up to day 49 p.i., but the knock-out 
mice no longer lost weight during infection. Thus, αβ CD3+ T-cells are necessary for both 
immunopathological symptoms and viral clearance. The transfer of 5x106 splenocytes resulted in 
recovery and clearance of the virus by day 11 p.i. Both TCR βδ-/- and TCRβ-/- knock-out mice 
also showed reduced weight loss; thus confirming the previous results. CD4 T-cell deficient or 
CD8 T-cell deficient mice still cleared the virus at day 11 p.i., although mice without CD4 T-
cells lost some weight (approximately 10% weight loss), while CD8 T-cell depleted mice lost 
minimal weight (approximately 5% weight loss). Depletion of both T-cell populations led to the 
disruption of viral clearance. A significant decrease in IFN-γ, TNF-α, MCP-1, IL-6, and IL-10, 
but not IL-12p70 in the BAL fluid of TCRβ-/- knockout mice was also observed. Finally, 
histopathology results showed that despite virus persistence, the TCRβ-/- knock-out mice had 
reduced pulmonary inflammation during a low-dose PVM infection (39). 
Additionally, mice deficient in the IFN-γ receptor, perforin, or tumour necrosis factor 
receptor (TNFR)p55 were administered either a low or high (> 3500 pfu) dose of PVM-15. 
These mice still cleared the virus by day 11 p.i. and also had similar weight loss compared to the 
wild-type mice. Interestingly, a high dose of PVM-15 within the TCRβ-/- knockout mice resulted 
in similar weight loss, delayed mortality and similar pulmonary inflammation as in the wild-type 
mice. Cytokine concentrations within the BAL fluid of these knockout mice compared to the 
wild-type mice still contained significantly decreased IFN-γ, MCP-1, and IL-10, and no 
differences in IL-12p70, but there was also a significant increase in TNF-α and no difference in 
IL-6 concentrations. Therefore, symptoms resulting from a low-dose PVM infection in C57Bl/6 
mice are T-cell dependent and immunopathological, while a high dose of PVM will still inflict 
symptoms with a pathological mechanism. Additionally, T-cells are necessary for viral 
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clearance, but not through IFN-γ, TNFRp55, or perforin mediated mechanisms. 
 
1.3 Indoleamine 2,3-dioxygenase (IDO)-1: An Enzyme and a Signalling Molecule 
 
IDO is a known immunological mediator, and there are two different proteins of IDO 
(IDO-1 and IDO-2) that are both found in monocytes and dendritic cells (DCs). Macrophages 
(40) and respiratory epithelial cells (41) are also known to only produce IDO-1. IDO-2 is a more 
recent discovery by Metz et al. (42) in 2007. IDO-1 is known to have both enzymatic and 
signalling activity (43) and is induced by factors such as IFN-γ, cytotoxic T-lymphocyte-
associated protein (CTLA)-4 and programmed cell death protein (PD)-1, (43, 44). There is, 
however, evidence that it can be suppressed by factors such as IL-4 and IL-13 (45, 46), although 
it seems these same cytokines can induce IDO enzymatic properties (47). Therefore, elucidating 
IDO suppressors has been controversial. There is also controversy regarding the enzymatic and 
signalling activity of IDO-2 (42, 43). Generally, IDO is shown to have tolerogenic functions by 
either depleting or suppressing the proliferation of Th-1 cells, (48, 49) thereby allowing Th-2 
proliferation and biased response, (9) or by inducing T-regs (50) or regulatory DCs (51, 52). This 
protein was first thought to be an inducible part of the host-defence system (53). Since then, 
detectable levels of IDO have been found without infection, and it has been identified as a vital 
part of immune regulation (54). As such, it has been extensively studied within cancer and some 
chronic diseases (52) for its immunosuppressive properties. Only recently has it also been 
studied within the scope of viral infections (55)  and asthma (56).  
 
1.3.1 Activation of IDO 
Many studies have been focused on the enzymatic activity of IDO; due to this, much is 
known about its enzymatic activation. For instance, Cheng et al. found that hepatic carcinoma-
associated fibroblasts (hCAFs) induce tolerogenic DCs through IL-6-mediated signal transducer 
and activator of transcription (STAT)3 activation (51). They found that hCAF stimulation led to 
DCs with fewer, shorter than usual, dendrites. However, stromal cell-derived factor (SDF)-α, 
known to be produced by hCAFs, still allowed for DC migration. Since hCAFs were stimulating 
DCs in a way that showed stunted activation, though also recruited DCs, it was necessary to 
identify the physiological changes within DCs stimulated by hCAFs. Cheng et al. used 
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fluorescence-activating cell sorting (FACS) to observe that hCAF-stimulated DCs showed 
expression levels similar to iDCs except for the deficient expression of CD83 (a maturation 
molecule) and exceptionally high expression of tolerogenic surface molecules CD14 and CTLA-
4. With this revelation made, the tolerogenic properties of these hCAF-stimulated DCs were 
deduced by comparing the production of pro-inflammatory or immunosuppressive cytokines 
within co-cultured CD3+ T-cells. It was found that pro-inflammatory cytokines IL-12p70, and 
TNF-β decreased while immunosuppressive cytokines IL-10 and TGF-β were induced. 
Additionally, overall T-cell proliferation was inhibited, while there was an increase of 
CD4+ CD25+ T-cells and CD4+ CD25+ Foxp3+ T-cells within these cultures. 
Along with this increase in phenotypical T-reg cells, there was also an increase in CD4+ 
T-cells producing IL-10 and a decrease in CD8+ T-cells producing IFN-γ within these cultures. 
Confirming that these DCs have tolerogenic properties, Cheng et al. inhibited IDO and STAT3 
using 1-methyl-tryptophan (1-MT) and S31-201, respectively. Both of these inhibitors reversed 
the tolerogenic and pro-inflammatory effects that hCAF-DCs had on the CD3+ T-cells. Since 
S31-201 gave the same T-cell phenotypes as IDO-inhibitor 1-MT, it was found that STAT3 is an 
inducer of IDO enzymatic activity within the hCAF-tolerogenic DCs. IL-6, a known STAT3 
inducer, was neutralized within the hCAF-DC medium, which leads to the decreased 
phosphorylation of STAT3 and inhibited IDO protein production. 
Additionally, exogenous IL-6 and SDF-α were able to induce STAT3 phosphorylation 
within mDCs together and on their own. This induction also led to increased protein production 
of IDO within these cells. Thus, hCAFs were able to stunt the normal maturation of DCs and 
induce tolerogenic DCs through the activation of IDO by the IL-6/STAT3 pathway. 
Rodrigues et al. did a study on IDO-1 expression of iDCs co-cultured with mast cells 
(MCs) (44). They confirmed that co-culturing of mast cells with iDCs led to the development of 
IDO-1+ DCs that were tolerogenic based on surface molecule phenotyping and high expression 
of IL-10. It was also confirmed that CD3+ T-cell stimulation with these MC-DCs suppressed 
proliferation and differentiation was T-reg skewed. These tolerogenic properties suggested that 
IDO-1 may be playing a role. IDO-1 was expressed by these MC-DCs but was not found within 
the iDC cultures. It was confirmed MCs do not degranulate when co-cultured with iDCs. 
Therefore, researchers blocked the histamine receptors H1 and H2 on iDCs to see if that affected 
IDO-1 expression. 
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Interestingly blocking the H1 receptor did induce more IDO-1 mRNA expression, but 
this did not translate to more IDO-1 protein production. Blocking the histamine receptors did not 
suppress IDO-1+ iDCs. Since neither degranulation nor MC components blocked IDO-1 
expression, they looked at other surface molecules of MCs. PD-1 was expressed on MC, and it 
was confirmed that both programmed death-ligand (PD-L)1 and PD-L2 on iDCs increased 
expression after co-culturing with MCs. When the co-cultures were given anti-PD-1, anti-PD-L1, 
and anti-PD-L2 separately, all of them suppressed IDO-1 protein production within the DCs. 
Furthermore, anti-PD-L1 also suppressed IDO-1 mRNA expression. STAT3 is a known 
inducer of IDO-1 expression, as previously shown by Cheng et al. (51). The researchers 
proceeded to observe the phosphorylation of STAT3 within the MC-DCs, and found a large 
amount of phosphorylated STAT3 (pSTAT3). Anti-PD-1 decreased phosphorylation, and the 
STAT3 inhibitor JSI-124 also inhibited this phosphorylation. Finally, this inhibitor ablated the 
IDO-1 mRNA expression and protein production within the iDCs. Rodrigues et al. concluded 
their study by looking at NFκB1, NFκB2, and suppressor of cytokine signalling (SOCS)3 mRNA 
expression, among other factors. They found that NFκB2 was highly expressed after culturing 
with MCs, and this was ablated by the addition of anti-PD-1. iDCs expressed NFκB1 without 
MC culturing, and this did not increase when MCs were added; anti-PD-1 did suppress some of 
its mRNA expression as well. Finally, SOCS3 expression was virtually ablated within the MC-
DCs, but administration of anti-PD-1 recovered this expression (44).  
It was also realized that inhibition of the janus kinase (JAK)1/3 pathway through 
tofacitinib induced IDO-1 expression within lipopolysaccharide (LPS)-stimulated monocyte-
derived DCs from rheumatoid arthritis patients (57). Kubo et al. showed that this inhibitor also 
decreased expression of CD80/86, IL-1β, TNF-α, and IL-6 proteins. These DCs co-cultured with 
T-cells but without any previous stimulation produced IFN-γ and IL-10 secreting cells; IL-10 
concentration was much lower than IFN-γ. When they were first stimulated with LPS and 
without tofacitinib, there was an increase in IFN-γ concentration and suppression of IL-10 
secretion. When tofacitinib was added to the LPS-stimulated DCs in a dose-dependent manner, 
IFN-γ concentrations dropped, and IL-10 concentrations increased. Tofacitinib was also 
confirmed to increase both IDO-1 and IDO-2 mRNA levels within these DCs in a dose-
dependent manner. This switch from IFN-γ secretion to IL-10 secretion did correlate with 
enhanced suppression of T-cell proliferation but did not correlate with T-reg proliferation since 
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these populations were stable despite the addition of tofacitinib (57). Therefore, IDO activation 
may be suppressed through activating the JAK1/3 signalling cascade; although suppression of 
this cascade seemed to induce switching of T-cell cytokine profiles from pro-inflammatory to 
tolerogenic without manipulating the tolerogenic T-reg cell population. Due to the contradictory 
results of these studies, IDO activation and suppression are shown to be complex but are still 
studied intensely in areas of cancer, chronic diseases, and infections because of its potential 
immunomodulatory and immunoregulatory aspects. 
 
1.3.2 Enzymatic activity 
IDO is the rate-limiting enzyme for tryptophan metabolism within the kynurenine 
pathway (40, 58). Depletion of tryptophan coupled with an increase in toxic tryptophan-
intermediates, leads to a change within the mononuclear cells’ environment and the extracellular 
environment where Tryp depletion can starve fungus, parasites and other microbes (59). This 
change, along with environmental chemokines and cytokines, will modulate the disease 
outcomes in contrasting ways. It has been shown that IDO-1 activity can lead to a Th-2 biased 
response through the induction of Th-1 apoptosis or attenuation of the Th-1 response (58). Both 
apoptosis and attenuation can be attributed to Tryp-depletion, according to Fallarino et al. and 
Munn et al., respectively (48, 60). 
Fallarino et al. first showed that 3- hydroxyantranylic acid (3-HAA), a metabolite of the 
tryptophan/kynurenine (tryp/kyn) metabolic pathway, administered to murine thymocytes 
increased apoptosis through either the condensation or the fragmentation of the cellular nucleus 
(48). Other kynurenines were also tested at physiologically relevant levels, and it was found that 
only 3-HAA and quinolinic acid (QUIN) were able to induce apoptosis at physiologically 
relevant levels. Then they exposed differentiated Th-1 and Th-2 cells specific for either 
ovalbumin (OVA) or P815AB, which is a tumour/self-antigen to 3-HAA or QUIN. When either 
kynurenine was administered to these cells, an increased percentages of Th-1 cells were 
apoptotic, while Th-2 cells were unaffected (48). Therefore, the kynurenine metabolites 3-HAA 
and QUIN can selectively induce apoptosis within Th-1 cells and skew a mixed Th-1/Th-2 
response to become a primarily Th-2 response. 
Meanwhile, Yun et al. identified the induction of antigen-specific T-reg cells due to IDO-
1 expression within the aorta (50). Ilic et al. also found that kynurenine depletion due to IDO-1 
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within DCs led to T-reg development within an in vitro human cellular model (61). Cheung et al. 
were also able to induce tolerogenic DCs that stunted T-cell proliferation. Additionally, any 
CD4+ T-cells were phenotypically T-reg and had high IL-10 production, which leads to an anti-
inflammatory state with both IL-10 and TGF-β cytokines. This state also leads to the decrease of 
cytotoxic T-cells producing IFN-γ and the general decrease of IL-12p70 and TNF-β (51). 
Both RSV (9) and PVM (unpublished data) have been shown to induce IDO-1 mRNA 
production during infection. Therefore, IDO-1 is a known player during infection and may play a 
role in the viral and immunopathology caused by both viruses. 
 
1.3.3 Signalling activity 
IDO signalling seems to be dependent on two immunoreceptor tyrosine-based inhibitory 
motifs (ITIM) within the protein. The binding of IL-6 or other pro-inflammatory factors on the 
cell’s surface promotes the phosphorylation of these ITIMs, which then interact with SOCS3. 
This interaction results in IDO’s proteasomal degradation (43). In contrast, TGF-β will lead to 
Fyn-mediated phosphorylation of IDO that eventually leads to noncanonical NFκB activation for 
an anti-inflammatory environmental induction (43). Observing the differences between the study 
done by Kubo et al. and the ones performed by both Rodrigues et al. and Cheng et al., the 
development of T-reg cells by tolerogenic DCs may be dependent on IDO’s enzymatic 
properties, while the shifting of proinflammatory T-cells towards a tolerogenic state may be due 
to IDO’s signalling activity. However, this is just speculation because Kudo et al. did not 
measure the kynurenine or tryptophan levels within the culture medium to see if there were any 
differences between DCs cultured with both LPS and tofacitinib and those only cultured with 
LPS. 
 
1.4 Asthma: Disease or Syndrome 
 
1.4.1 Asthma development and epidemiology 
Asthma is a commonly known chronic inflammatory disease that affects the conducting 
airways of an individual (62). The most common symptoms of asthma include shortness of 
breath, difficulty in breathing, coughing and wheezing (63, 64). This condition was traditionally 
caused by an exacerbated Th-2 – biased response towards common molecules (dust, smoke 
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particulates, chitin from insects) (62). Recently, it has been discovered that asthma is not as 
simple as first thought. Asthma can have an allergic phenotype, also known as atopic asthma, or 
an intrinsic one. The allergic phenotype is characterized by IgE production towards an allergen 
and is initiated through sensitization of said allergen (62), and the common symptoms in allergic 
asthma are caused by high mucus production, and airway narrowing and obstruction (64). 
Intrinsic asthma does not produce IgE towards an allergen, nor has any distinct function for the 
adaptive immunity (62). Its development and exacerbation have been a topic of many studies 
with a plethora of different mouse models and combinations of mice, viruses, and allergens (65).  
 
1.4.2 Implications of the Immune System 
Asthma can also be defined by the prominent cell type that influxes during exacerbation. 
Even with this definition, asthma is still considered a spectrum disorder where individuals may 
exhibit eosinophilic influx while others experience neutrophilic influx. Of course, other 
individuals develop a combination of both eosinophilic and neutrophilic influx. These can also 
be sub-defined based on differing cytokine and chemokine production (62). Some studies have 
shown an increase in eosinophilic infiltration during RSV and other respiratory infections that 
increases wheezing during and after severe infections (15, 17). Tang et al. suggest that 
exacerbation of asthma by RSV induces a neutrophilic influx of cells within the lungs (66). 
These different types of cellular influx are mirrored by the previously mentioned strains of PVM 
virus, where a neutrophilic or eosinophilic response has been shown depending on the virus 
strain and mouse strain. 
B-cells produce IgE to a specific antigen and release it into the serum. Mast cells have 
FCεRI receptors that tightly bind the Fc portion of IgE as they are both travelling through the 
blood. These cells develop in the bone marrow and travel through the blood to their designated 
tissues (generally under the skin, and in the mucosal area such as the lungs) (67, 68). When two 
bound IgE molecules bind to one molecule of their specific antigen, they cross-link initiating a 
signalling cascade that leads to mast cell degranulation. These cells hold a multitude of 
cytokines, proteases, and most of the histamine found within the human body in their granules 
(67). Mast cells produce and secrete cytokines such as TNFα, IL-4, IL-5, IL-6, IL-1β and IL-13 
(67). These mast cells are part of the early response during exacerbation of an allergic response. 
The cytokines and other mediators that are released are involved in bronchoconstriction of the 
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airways, mucus secretion of goblet cells, and the secretions of chemokines leading to the 
infiltration of other cell populations such as macrophages, eosinophils, neutrophils, and T-cells 
(69). These cells, are part of the later phase of asthma which typically leads to prolonged airway 
dysfunction and damage (69).  
Yu and Chen established three different asthmatic models using OVA and a mixture of 
LPS at different time-points in order to develop an eosinophilic model, a neutrophilic model, and 
a mixed eosinophilic and neutrophilic model (70). When the mice from all three models were 
exposed to methacholine, all developed strong airway resistance; treatment of dexamethasone to 
reverse the resistance was only successful within the eosinophilic model. Cellular influx within 
the BAL fluid confirmed the establishment of the type of asthmatic model developed. The agents 
used in the eosinophilic model induced approximately 50% eosinophilic, less than 5% 
neutrophilic, and 40% macrophage influx. The agents used in the neutrophilic model induced 
less than 10% eosinophils, 60% neutrophils, and 20% macrophage influx, while the agents used 
in the mixed model induced approximately 20% eosinophils, 50% neutrophils, and 20% 
macrophages. Detection of lymphocytes within all three models was between 5-10% with no 
significant difference found between them and the negative control. The largest number of total 
cellular influx with about 1.5x107 cells was found in the mixed model; the neutrophil model was 
second with about 5-10x106 cells, and the eosinophilic model was third with approximately 
5x106 cells. In the eosinophilic model large amounts of IL-4, IL-5, and IL-13 (100, 80, and 50 
pg/mL respectively), a large amount of IL-33 (50 pg/mL), and minimal IFN-γ and IL-17A (less 
than 20 pg/mL) was induced. In the neutrophilic model minimal IL-4, IL-5, and IL-33 (less than 
20 pg/mL), and a large induction of IL-13, IL-17A, and IFN-γ (40, 300, and 75 pg/mL) were 
observed. Finally, in the mixed model a large amount of all proteins: 175 pg/mL of IL-4, 90 
pg/mL of IL-5, 75 pg/mL of IL-13, 70 pg/mL of IL-33, 300 pg/mL of IL-17A, and 
approximately 85 pg/mL of IFN-γ was found. Finally, total IgE was significantly increased in all 
three models (at least 600 ng/mL). The eosinophilic model resulted in higher induction of OVA-
specific IgE compared to the other two models, and the neutrophilic one resulted in the smallest 
production though it was still significantly higher than the negative control group. Therefore, the 
eosinophilic model established here results in high IgE production, large eosinophilic and some 
macrophage influx, and minimal neutrophilic influx. These cells were coupled with large Th-2 
cytokines (IL-4, IL-5, and IL-13), and minimal Th-1 and Th-17 cytokines (IFN-γ and IL-17A). 
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Contrastingly the neutrophilic model resulted in a large neutrophilic influx with minimal 
eosinophilic and macrophage influx. These cells were coupled with high IL-17A, IL-13, and 
IFN-γ production and minimal IL-4 and IL-5 production; some IgE production was also detected 
within this model. In the mixed model similar cellular influx was observed as in the neutrophilic 
model, but high IgE induction and high concentrations of all cytokines measured were also 
observed. 
A review in 2000 by Wardlaw et al. (71) confirmed typically increased eosinophilia 
within the airway submucosa of asthmatic patients, but not enhanced neutrophils. Bronchoscopy 
studies allowed for the quantification of lymphocytes and mast cells that also have a significant 
role in this disorder but stay within the epithelium. Eosinophils are known to both induce damage 
in the airways and activate portions of the adaptive immune system (69). Eosinophil secrete 
factors such as eosinophil peroxidase which is known to cause bronchial hyper-responsiveness 
directly, damage the structural cells of the lungs, and activate DC’s for an adaptive immune 
response (62). Eosinophils also secret major basic protein which causes damage to the structural 
cells (62).  
Contrastingly, neutrophils travel to an inflamed site and secret molecules such as 
granzymes and reactive oxygen species to create a hostile environment towards viral, bacterial 
and fungal infections (72). These molecules are also able to damage the epithelial layer in these 
infection sites. Typically, neutrophils can survive up to 6-8 hours when circulating; though 
tissue-based neutrophils may survive 3-5 days and reverse transmigrate back into the circulation 
(72). Th-17 cells recruit neutrophils into a site through IL-17A induction of epithelial cells to 
secrete IL-8, a known neutrophil chemokine. Neutrophils can express FCεRI that bind to IgE; 
thus modifying responses when IgE binds to their antigen (72). The neutrophil role in modifying 
the airways is still controversial, but the secretion of TGFβ, elastase, and matrix 
metalloproteinase 9 by neutrophils do confirm this possibility (72). Therefore, despite 
neutrophils commonly found in intrinsic asthmatic sputum, their role within the mechanisms of 
asthma remains unclear. 
 
1.4.3 Effects of cockroach allergen on allergy development 
Cockroach particles constitute one of the many benign macromolecules that are known 
allergens associated with the development of asthma (73). According to Gao, despite other 
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common allergens such as animal dander and house dust mites also correlating with asthmatic 
development, CRA seems to be the most substantial risk factor. This increased risk due to CRA 
was especially common within inner-city children cohorts, who had both increased severity and 
frequency of childhood allergies and asthma. Gao reported that approximately 50% of children 
who tested positive for CRA were also more likely to have high levels of CRA within their 
bedrooms, and this group was considerably more likely to be hospitalized, and miss more days at 
school due to asthma-related symptoms and exacerbations (73). 
In a study performed by Whitehead et al., an asthmatic mouse model was developed that 
utilized the sensitization of OVA alone, and when paired with known allergens correlated with 
increased asthmatic cases (74). They used house dust mite allergen (HDM), LPS, flagellin, 
Aspergillus (fungus) protease (asp), or papain protease (cysteine protease from papayas) (pap) as 
adjuvants for their OVA sensitization. This study differentiated the asthmatic responses towards 
OVA when sensitized with either a protease (HDM, asp, and pap) or TLR ligands (LPS and 
flagellin). They confirmed that OVA sensitization on its own did not induce airway inflammation 
when the mice were further challenged, but there were differences in cell population influxes and 
cytokine production when OVA was coupled with either a protease or a TLR-ligand adjuvant. 
Whitehead et al. found that, generally, TLR-ligands induced the production of TNF and IL-1β 
towards OVA, while the protease adjuvants did not. Additionally, the TLR-ligands induced a 
mixed eosinophilic/neutrophilic influx coupled with a mixed Th-2/Th-17 cytokine profile. They 
also showed that TNF was needed during the sensitization phase of the TLR-ligand asthma 
model since eosinophilic influx was decreased when the model was tested in a TNF-deficient 
mouse-strain. The protease adjuvants generally produced an eosinophilic influx with a primarily 
Th-2 cytokine profile. The HDM adjuvant seemed to show a mixture of protease and TLR-ligand 
response. Additionally, none of the adjuvants used induced IFN-γ production (74). Therefore, 
there is a difference between asthma induced by protease allergens and those induced by TLR-
ligand allergens. 
Kim et al. tested the effect of CpG oligodeoxynucleotide in a CRA-induced asthmatic 
model (75). Focusing on the CRA-induced model, the frequent intranasal sensitization of the 
Balb/c mice with CRA lead to significant airway hypersensitivity resistance and an influx of 
cells within the BAL fluid. Primarily, these cells consisted of neutrophil and macrophage 
populations, but also contained a small but significant eosinophilic population when compared to 
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their sham group. Additionally, total lung samples showed significantly decreased percentages of 
alveolar macrophages, inversely correlated with significantly increased percentages of interstitial 
macrophages and monocytes. Kim et al. showed that the CRA model induced a Th-2 (IL-5 and 
IL-13) biased response with increased total IgE, and CRA-specific IgE production. The CRA-
specific IgG1/IgG2a ratio was also significantly increased within the CRA model. There was 
also nominal IFN-γ protein production. Additionally, there was an increase in IL-10 production 
but no change in phenotypic T-reg cell percentages (75). Therefore, this CRA model induced a 
mixed eosinophil/neutrophil influx coupled with a more Th-2 biased response. Coupling this 
with the study done by Whitehead et al., CRA most-likely induces an asthmatic response based 
on TNF expression suggesting a TLR-ligand-like induction by CRA. 
In an earlier study, Kim et al. focused on the protease activity of CRA (76). Here, CRA 
protease activity was determined to be significantly inhibited by a serine-protease inhibitor 
(aprotinin), and this caused slightly more inhibition than a cysteine protease inhibitor, a serine-
cysteine protease inhibitor, or a trypsin inhibitor. Protease-activated receptor (Par)-2 
internalization was tested with either an alveolar macrophage or a peritoneal macrophage cell 
line. Each cell line was administered CRA with or without aprotinin, and both showed Par-2 
internalization by CRA; this was inhibited with aprotinin treatment. Both cell lines also produced 
TNF-α when exposed to CRA. This induction was also ablated with aprotinin treatment. Kim et 
al. then used a Par-2 antagonist (ENMD-1068) and found that CRA could neither induce 
internalization of Par-2 nor production of TNF-α. CRA also induced cell influx that was 
primarily composed of neutrophils, macrophages, and lymphocytes; there was also a small 
number of eosinophils. The cytokine profile of this CRA model showed a Th-2 biased response 
with a high concentration of IL-13 and similar, but lower, concentrations of IL-5 and IFN-γ. 
There was also an increase in IgE titers within the model. Blocking of TNF-α ameliorated the 
pulmonary inflammatory symptoms. Kim et al. then incubated CRA with aprotinin before 
sensitizing mice with the combination. This removal of serine protease activity attenuated airway 
inflammation and decreased alveolar macrophage influx and TNF-α expression. However, 
aprotinin treatment did not affect interstitial macrophage or DC influx (76). Therefore, CRA 
exhibits serine protease activity that leads to the induction of TNF-α and subsequent airway 
inflammation and asthmatic conditions. 
As such, CRA is a potent immunostimulant and apparent inducer of asthmatic conditions, 
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although the type of asthma is dependent on how sensitization is done, and whether a viral 
infection is introduced before or after initial CRA exposure. 
 
1.4.4 Clinical symptoms 
According to the Asthma and Allergy Foundation of America (AAFA), asthma is a 
chronic inflammation of the lungs that generally manifests as difficulty breathing. Asthmatic 
symptoms include coughing, wheezing, shortness of breath, rapid breathing and chest tightening 
(63). The problem is that this set of symptoms does not account for the multiple ways that they 
can be manifested. Triggers for these asthmatic symptoms include allergens that the host has a 
corresponding allergic response against (cat dander, dust mites), or general irritants such as 
smoke, air pollution, and aerosolized chemicals. The AAFA even states that exercise and mood-
swings are known triggers due to their systemic hormonal changes within the body that can 
affect lung function. Asthma is sub-divided into different categories dependent on the triggers for 
clinical symptoms and other biological factors. These factors are more readily available for 
monitoring because of the technological advances, and overall better monitoring systems, within 
hospitals and other care facilities. 
Allergic asthma is the well-known classical trigger of asthma. Its development occurs in 
early-life, and exacerbation occurs due to exposure of an allergen towards which the host has a 
Th-2 biased response, including IgE involvement (77). Non-allergic asthma is slightly more 
complicated as onset is usually later in life, and exacerbation occurs without any specific trigger. 
Additionally, no allergen-specific IgE is found within the serum of these patients (77). 
Wenzel et al. also describes how unbiased studies were done that had a plethora of 
different clinical variables such as the age of onset, gender, eosinophilia, and emergency-room 
visits, but also did not contain measurements of airway obstruction such as FEV1 (77). Despite 
these drawbacks, most of the studies discussed here found general groupings for the known sub-
categories of asthma. These included early-onset being a key factor for more allergic asthma, but 
could not distinguish any variables that are more linked to the different severities of exacerbation 
seen within the observed cohorts. Late-onset asthma seemed to better cluster with other factors 
such as eosinophilic influx, and obesity. Primarily, this cohort was comprised of women and did 
not have an allergen that triggered exacerbation (77). 
These subdivisions of asthma based on clinical symptoms outline how critical it is to 
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deduce the different pathways that can induce its development and exacerbation. These different 
pathways that can lead to similar symptoms show how complicated asthma is, and suggests that 
more than one model is necessary to determine all of the different factors of asthmatic 
development and exacerbation.  
 
1.4.5 Viral induction of asthma development or exacerbation 
The complexity of how respiratory viruses play a role in asthma is not only limited to its 
development. There are also studies showing that acute respiratory infections can either induce 
(78, 79) or suppress (18) asthma exacerbation. 
John et al. used a model of CRA asthma that developed due to environmental changes 
within the lungs because of a previous viral infection (79). This model was initiated with viral 
infection occurring on day 0 and the mice were first sensitized to CRA in incomplete Freud’s 
adjuvant (IFA), either intraperitoneally or subcutaneously on day 21. This long time-period 
between infection and sensitization allowed the virus to clear before the mouse immune system 
would respond to CRA. The mice were again sensitized to CRA intranasally two weeks after the 
first sensitization (day 35). Subsequently, they were challenged with an intratracheal 
sensitization of CRA a week later (day 42) and then sacrificed the next day (day 43). They had 
previously shown that RSV infection induced IL-13, which further induced the chemokine 
CCL5. Therefore, they tested the effects of administering anti-CCL5 within this asthmatic 
model. John et al. showed that RSV infection prior to CRA sensitization led to significantly 
increased eosinophilic influx. This eosinophilic influx was significant, but small, in comparison 
to the overall neutrophilic influx induced by CRA. Neither cellular influx was affected by RSV 
infection or anti-CCL5 treatment. RSV infection did induce a significantly higher lymphocyte 
influx when compared to the CRA group without RSV infection and the CRA/RSV group treated 
with anti-CCL5. Strangely, only CCL22 was inhibited by anti-CCL5 treatment, whereas neither 
CCL6 nor CCL11 showed any significant changes (79). John et al. suggest that there are long-
lasting changes due to RSV infection, even after viral clearance, that are mediated by CCL5 
production during the viral infection. There is a further suggestion that these changes manipulate 
how the lungs respond to CRA sensitization, and they seem to make the lungs permissible for 
asthma development.  
Smit et al. identified CD8+ T-cells and their IFN-γ production induced by RSV infection 
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as a necessary component for regulating asthmatic symptoms (18). Smit et al. initiated the study 
by assessing the different responses towards RSV infection, CRA sensitization, or RSV infection 
followed by CRA sensitization, from both C57Bl/6 and Balb/c strains. The C57Bl/6 mice had 
decreased airway hypersensitivity when CRA and RSV were coupled compared to CRA 
sensitization on its own. The RSV+CRA group of Balb/c mice showed an increased airway 
hypersensitivity compared to the RSV infected group, but similar resistance levels to mice 
sensitized to CRA. Additionally, IL-4 was only induced in the Balb/c mice. Similar levels were 
found after either RSV infection or CRA sensitization, but this IL-4 induction was significantly 
increased when CRA sensitization was coupled with RSV infection in the BALB/c mice. The 
C57Bl/6 strain did not show any IL-4 induction. However, it did show the induction of IL-5 
within the CRA sensitized group to similar levels as Balb/c, although this was also significantly 
reduced when CRA was coupled with RSV;  the Balb/c strain showed an increase in IL-5 
secretions when RSV and CRA were coupled. This trend was mirrored when Smit et al. 
observed the IL-13 protein secretions. 
Since C57Bl/6 mice had an attenuated CRA-induced Th-2 response when CRA was 
coupled with RSV, they investigated further by addressing whether this phenotype was only 
apparent when CRA was administered after RSV viral clearance. The researchers also tested 
whether RSV infection and viral clearance occurred after the initial CRA sensitizations and 
before the subsequent CRA challenges. Both models of RSV infection and CRA sensitization 
and challenges significantly decreased airway hypersensitivity resistance compared to the CRA 
models without the supplementary RSV infection. C57Bl/6 mice are resistant to viral infections 
due to their ability to induce a more rapid and robust Th-1 response (21). Therefore, the 
researchers added anti-IFN-γ to their sensitization protocol. This suppression of IFN-γ activity 
increases airway hypersensitivity resistance while also increasing eosinophil influx not seen 
without the anti-IFN-γ treatment. This time, there was an increase in IL-4 production from the 
group that was only sensitized to CRA, and this induction was significantly increased when anti-
IFN-γ was administered. The antibodies inhibited the suppression of IL-4 production by the 
additional RSV infection. This trend was also seen when observing the IL-5 and IL-13 levels 
within these mouse groups. Finally, Smit et al. injected RSV-primed CD4+ or CD8+ T-cells 
within CRA sensitized mice one day before they were challenged. Airway resistance was only 
decreased when RSV-specific CD8+ T-cells were administered, though both populations of T-
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cells decreased IL-5 production and increased IFN-γ production. IL-13 had a nominally 
significant decrease when CD8+ T-cells were administered. This decrease was not seen when 
CD4+ T-cells were similarly administered (18).  
Therefore, Smit et al. found that RSV infection, whether during asthma development or 
exacerbation, inhibited the asthmatic phenotype within C57Bl/6 mice. These results are in 
contrast to the study by John et al., which suggested that RSV infection before sensitization 
would induce an asthmatic phenotype within DBA2J mice. Thus, the role that viral respiratory 
infections play within the development and exacerbation of asthma needs further elucidating, 
with multiple different models. The differing models are imperative in understanding the 
differences in asthma phenotypes, and what signalling pathways control their development and 
exacerbation. 
 
1.4.6 Management of asthma 
According to the AAFA, asthma is best managed by a combination of avoiding known triggers, 
especially apparent within atopic asthma, and treatment of steroids with or without beta-agonists, 
or leukotriene modifiers, biologicals, or theophylline (63). This list is inclusive of all long-lasting 
medication that may be prescribed for long-term treatment of the asthmatic condition. There is 
also short-lasting treatment with steroids with or without beta antagonists that are used when an 
exacerbation or ‘asthmatic attack’ occurs (63). These guidelines outlined by the AAFA stem 
from the original guidelines produced by the Global Initiative for Asthma (GINA), which was 
founded just over 25 years ago in 1993 (80). GINA was founded by a number of organizations 
focused on asthma and other lung diseases in order to assist in asthmatic patient care. This was 
done by compiling and distributing a document of guidelines which was first published in 1995 
(80). Since then, the GINA guidelines have been modified and updated every year as our 
understanding of the intricacies of asthma has grown. As with most topics in science, new 
discoveries leading to better categorization of asthma and therefore treatments have also led to 
more questions that need to be followed up with more basic research. 
A survey was done in 1999 that assessed patient’s opinion on the level of controlling 
asthmatic symptoms and was used as an extrapolation to how the guidelines were distributed to 
these patients (81). Shocking results were obtained from this survey. These results included a 
dissonance between the GINA guidelines’ definition of controlled asthma, and the patient’s 
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perception of how controlled their asthma was. Only 4.6% of children and 7.7% of adults self-
assessed their asthma as severe, despite 15.1% of children and 20.5% of adults being diagnosed 
with severe asthma according to the GINA guidelines. Additionally, 23% of adults have made 
career choices dependent on their asthma, while the GINA guidelines suggest that fully 
controlled asthma should not limit any life activities. Finally, the GINA guidelines recommend 
having a lung function test, but over half of both adults and children have never had this test 
(81). Conclusions pulled from this study suggested that either patients were content with defined 
sub-optimal control, or physicians are not as knowledgeable concerning the severity levels of 
asthma. 
In 2007, a report was produced during the National Asthma Education and Prevention 
Program (NAEPP) that updated these GINA guidelines (82). The updates included better guides 
for assessing the severity of asthma and for assessing its control after treatment had started. Also 
included was a more specialized and understandable table. This table was designed to assist in 
the long-term management of asthma, which included modifications to treatment strategies, and 
new multifaceted ways of educating patients to assist in the empowerment of controlling their 
asthmatic condition (82).  
 Thus, the management of asthma is constantly being scrutinized and updated to reflect 
the latest studies in all aspects of asthmatic disease. These aspects include new medicine for 
control, and better methods for assessment of both severity and quality of control strategies. As 
research continues to elucidate the differences in phenotypes and asthma development, the GINA 
guidelines will continue to give this pertinent information to physicians so that they can make 
better-informed decisions to help patients control their asthma. Additionally, the GINA 
guidelines can be used by patients to help them better understand their conditions. Finally, the 
GINA guidelines stress the importance of free communication between patient and physician, so 
that diagnosis of severity and assessment of control measures occur without much delay. 
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2 HYPOTHESIS AND OBJECTIVES 
 
There are four rationales for my hypothesis, and they are as follows: 
1. Early RSV infections are linked to the development of asthma (3, 15, 17) 
2. PVM-15 within the Balb/c adult mice is an established model for infant RSV infection 
(21, 22, 24) 
3. Traditional asthma is a Th-2 exacerbated response towards a benign particulate allergen 
(62) 
4. IDO-1 is known to either upregulate inducible T-regs (50, 61) or suppress the Th-1 
response allowing the proliferation of Th-2 responses (9) 
 
Therefore, I hypothesize: an underlying PVM infection during the first exposure towards an 
allergen will alter the memory response towards it, thus promoting the development of an 
asthmatic response. 
 
There are three objectives to confirm this hypothesis: 
1. Develop an asthmatic model using PVM-15 and 5-6 week old Balb/c mice to reproduce a 
severe RSV infection, and lyophilized-ground German Cockroaches as the allergen 
(CRA). 
2. Elucidate the lung environmental response 24 hours after either CRA exposure or 
clearance of a PVM infection within three groups using the developed asthma model: 
negative control group exposed to medium followed by PBS (Medium/PBS), CRA group 
exposed to medium followed by CRA (Medium/CRA), and PVM group (PVM/PBS). 
3. Examine the lung environment of the experimental group exposed to PVM followed by 
CRA (PVM/CRA) using the model based on changes within the immune response such 
as protein production, mRNA expression, and cellular efflux and influx.  
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3 MATERIALS AND METHODS 
 
3.1 Cell line and virus propagation 
 
Baby Hamster Kidney (BHK)-21 cell line was initially obtained from the American Type 
Culture Center (ATCC) to grow my PVM stock. The origin of the PVM stock is also ATCC. The 
BHK-21 cells were grown in BHK-21 medium. The BHK-21 medium consisted of Minimum 
Essential Medium (MEM) from Sigma-Aldrich supplemented with 0.1 mM non-essential amino 
acids, 1 mM Sodium Pyruvate, and 5 µg/mL Gentamicin, all from Thermo Fisher Scientific. It 
was also supplemented with 5% fetal bovine serum (FBS) from Gibco Thermo Fisher Scientific. 
These cells were grown to a confluence of ~80% within T-150 flasks from BD Biosciences and 
passaged approximately 3-4 times before being used for virus propagation and titration. 
At approximately 75-80% confluency of passage 3 or 4, the medium was removed, and 
the cells were gently washed with PVM medium. This medium consisted of  Dulbecco’s 
Modified Eagle Medium (DMEM) base from Sigma-Aldrich supplemented with 0.1 mM non-
essential amino acids, 10 mM HEPES Buffer, (21) 5 µg/mL Gentamicin (all from Thermo Fisher 
Scientific), and 2% FBS (Gibco Thermo Fisher Scientific). Once washed, the cells were infected 
with PVM at a multiplicity of infection (MOI) of 0.1 within 5 mL. The flasks were manually 
rotated every 15 minutes at 37 °C and 5% CO2 for 1.5 hrs. Subsequently, an extra 11 mL of 
PVM medium was added, and the cells were incubated in the same conditions, without rotation, 
for 3 days. On that third day, the virus was harvested by scraping the cells from the flask using a 
39 cm handle/3.0 cm blade cell scraper from Corning Inc. The cells were further disrupted by 
pipetting them up and down multiple times within the spent medium. Once thoroughly mixed, 
the solution was aliquoted, and immediately frozen using liquid nitrogen. The frozen aliquots 
were stored in the minus 80 °C freezer for long-term use including more propagation of this 
virus as a stock for the mouse trials. 
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3.2 Cockroach allergen preparation 
 
Lyophilized German Cockroach Antigen (Blattella germanica) from Stallergenes Greer 
was resuspended at a concentration of 5 µg/µL in PBS from Gibco Thermo Fisher Scientific. It 
was aliquoted and stored at -20 °C for long-term use.  
 
3.3 Sample preservations 
 
3.3.1 Lung tissue 
All lung tissues were collected from the mice and aliquoted as described below. After 
collection, the smallest section of the multi-lobe was collected into a 2 mL screwcap tube 
containing 2.99-3.01 g of 2.4 mm zirconia beads from BioSpec Products Inc and 1 mL of 
TRIzol® reagent from Thermo Fisher Scientific. It was then homogenized in a mini bead-beater 
from BioSpec Products Inc for 10 seconds at 4,800 rpm, centrifuged in 4 °C at 10,000 rpm for 1 
min, frozen in liquid nitrogen, and stored at -80 °C for future mRNA extraction and qPCR 
analysis. 
The middle section of the multi-lobe was also removed into a 2 mL screwcap tube with 
2.4 mm zirconia beads, and 1 mL of sample medium consisting of DMEM supplemented with 
0.1 mM non-essential amino acids, 10 mM HEPES Buffer, 5 µg/mL gentamicin, and 1X 
antibiotic/antimycotic from Thermo Fisher Scientific. These samples were also homogenized and 
centrifuged in the same way, and then aliquoted into new 2 mL screwcap tubes, frozen in liquid 
nitrogen and stored at -80 °C for either virus titration assays or multiplex ELISAs. 
The largest section of the multi-lobe was inserted into a sterile 15 mL Falcon centrifuge 
tube from Thermo Fisher Scientific containing 2 mL of lung fragment culture (LFC) medium. 
This medium consisted of RPMI 1640 (1X) from Gibco Thermo Fisher Scientific, with 10% 
FBS, 10 mM HEPES, 0.1 M non-essential amino acids, 1 M Sodium Pyruvate, 2 mM L-
glutamine, 1X antibiotic/antimycotic, and 5 µg/mL gentamicin. They were transported on ice 
from the sampling room to a biosafety cabinet (BSC) where they were chopped into two pieces; 
each piece was deposited into 2 wells pre-prepared (the same day) with 500 µL of LFC medium 
and incubated at 37 °C and 5% CO2 until needed. Once the two pieces were distributed, they 
were minced with scissors from Thermo Fisher Scientific and left to incubate for 5 days at 37 °C 
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and 5% CO2. On day 5, 2 wells/mouse were pooled into a Fisherbrand 1.5 mL MCT Graduated 
Natural tube from VWR and centrifuged for 1 minute at 10,000 x g. They were then aliquoted 
into three 2 mL screwcap tubes and frozen/stored at -80 °C for total IgE analysis. 
The single-lobe was pooled per mouse group into a gentle MACS C tube from Miltenyi 
Biotech with 5 mL of Hans Balanced Salt Solution (HBSS) from Gibco Thermo Fisher Scientific 
supplemented with 5% FBS.  The tissue was then mechanically disrupted using a gentle MACS 
dissociator from Miltenyi Biotech, according to the manufacturer’s instructions. Then, 0.5 
mg/mL of Collagenase type IA and 20 µg/mL of type IV Bovine Pancreatic DNase (both from 
Sigma-Aldrich) were added to the homogenate, and the tubes were incubated in a 37 °C hot 
water bath for 20 min. The homogenate was then further dissociated into a suspension using the 
same gentle MACS dissociator and transferred to a 50 mL Falcon centrifuge tube. The 
suspensions were centrifuged, and the supernatant was decanted. Any red blood cells were lysed 
using 2 mL of ACK lysis buffer from Thermo Fisher at room temperature for 30 seconds. The 
buffer was neutralized with approximately 13 mL of lung tissue wash buffer. This buffer 
consisted of PBS with 0.5% bovine serum albumin (BSA) from Thermo Fisher Scientific. Once 
the buffer was neutralized, the samples were centrifuged. They were subsequently washed with 
the same wash buffer and passed through a 40 µM nylon cell strainer from Thermo Fisher 
Scientific. A Beckman Coulter Counter from Beckman Coulter Inc was used to determine the 
total cell count, and the cells were centrifuged and resuspended in the corresponding volume at 
4x107 cells/mL, to be used for FLOW cytometry analysis of different cell populations. 
 
3.3.2 Bronchoalveolar lavage (BAL) fluid 
The lungs were rinsed with 700 µL of PBS with 2% FBS and 3 mM EDTA (7.5% 
disodium ethylenediaminetetraacetic acid.2H2O). The rinse was pooled per group in a 15 mL 
Falcon centrifuge tube or collected individually for some experiments in a 2 mL screwcap tube 
and set on ice for processing after sampling had completed. The samples were spun and the 
supernatants aliquoted for IgE and Multiplex ELISA analysis, frozen and stored as described 
above. The cells were resuspended in Facola (0.03% sodium azide and 0.2% gelatin in PBS pH 
7.3) and processed for FLOW cytometry. 
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3.3.3 Blood samples 
The mice were euthanized with an overdose of isoflurane and then subjected to cardiac 
puncture. Blood was collected in a BD Microtainer Serum Separator Tube and spun at 10,000 xg 
for 3 min, then frozen and stored at -20 °C for later use. 
 
3.4 Virus titration assay 
 
96-well plates were seeded with 15,000 BHK-21 cells per well. Approximately, 15-20 
hours later, the lung homogenate samples and PVM virus stock, as a positive control, were 
defrosted and diluted, in PVM medium, 1/10 in the top row of a 96-well dilution plate. Each 
sample was plated twice for accuracy and serially diluted 1/10 down the plate. The medium from 
the BHK-21 plate was pipetted off and replaced by the samples in the dilution plate. The plates 
were then incubated at 37 °C and 5% CO2 for 3 days. 
On the third day, 100 µL of 25% acetic acid 75% ethanol was added to each well on top 
of the medium, and the plates were incubated at room temperature for 20 min to fix the cells. The 
supernatant was decanted, and plates were washed with 1X-PBS 4 times and tapped dry. Then, 
100 µL of a permeabilizing and blocking solution consisting of PBS with 20% FBS and 0.2% 
Triton X-100 was added to the fixed cells, and the plates were incubated at 37 °C for 30 min. 
The primary antibody solution (1X PBS with 5% heat-inactivated (HI)-FBS, 1% HI-goat serum, 
and 1:500 rabbit anti-PVM antibody) was added, and the plates were incubated under the same 
temperature for 2 hrs. The plates were rewashed 4 times with 1X-PBS and 0.5% Tween and then 
tapped dry. Then 100 µL of the secondary antibody (1X PBS with 5% HI-FBS, 1% HI-goat 
serum, 1:1000 alkaline phosphatase-conjugated goat anti-rabbit IgG) was applied, and the plates 
were again incubated for 1 hr. After this incubation, the plates were rewashed with 1X-PBS, and 
BIORAD AP Conjugate Substrate was added to each well. The plates were incubated at room 
temperature for approximately 20 min. The reaction was stopped by washing the plates with 
dH2O. The wells were filled with dH2O and read using an inverted microscope. Virus plaques 
were counted, and dilutions were accounted for when reporting the titers of viable virions.  
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3.5 qPCR RNA procedure for analysis of mRNA expression 
 
3.5.1 Isolation of mRNA from homogenate lung tissue 
TRIzol samples were defrosted in an RNase/DNase-free fume hood and left at room 
temperature for another 5 min. 500 µL were collected into a 1.5 mL DNase and RNase Free 
Graduated Microtube from FroggaBio, and 100 µL of chloroform was added to this aliquot. 
They were shaken for 15 seconds and left at room temperature for 2-3 minutes. The tubes were 
centrifuged using the Centrifuge 5415 R machine set at 4 °C for 15 min at 12,000 xg. The clear 
chloroform layered at the top of the sample solution was carefully removed and collected in 
another microtube. Then, 250 µL of isopropanol was used to precipitate the RNA from the 
separated chloroform solution by letting it sit for 10 min after multiple slow inverts. The samples 
were centrifuged at the same temperature and speed for an additional 10 min. After this 
centrifugation, the supernatant was pipetted off, and 500 µL of ethanol was added for washing. 
The samples were again centrifuged at 4 °C for 5 min at a speed of 7,600 xg. The ethanol was 
pipetted off again, and the tubes were left to dry for approximately 20-30 min. This drying was 
to let any remaining ethanol dissipate. The dried samples were then dissolved in RNase and 
DNase-free dH2O and frozen/stored at -80 °C overnight. Once all RNA had been extracted from 
all of the samples, they were defrosted on ice. Their 260/280 ratio, 260/230 ratio, and 
concentrations in ng/µL of each sample were then determined by using the ND-1000 
Spectrophotometer and corresponding ND-1000 V3.8.1 software. An aliquot of each sample was 
diluted to 100 ng/µL and used for preparing cDNA. 
 
3.5.2 Transcription to cDNA for qPCR 
Using the QuantiTect Reverse Transcription kit from Qiagen, a 500 ng aliquot of each 
sample was prepared in 60 µL of RNase and DNase-free dH2O as instructed by the manual. 
These cDNA samples were used for qPCR analysis. 
 
3.5.3 qPCR and data analysis 
The qPCR was run as per the instruction manual for PowerUP SYBR Green from 
Thermo Fisher Scientific. All of the primers were ordered from Thermo Fisher, and their 
annealing temperatures were identified in-house using gradient PCR. Table 3.1 lists the primer 
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sequences and corresponding annealing temperatures. The qPCR reaction was performed in the 
following way: 1st step at 50 °C for 2 min and then 95 °C for another 2 min. The 2nd step was 
repeated 40X starting with 15 sec at 95 °C, 30 sec at the annealing temperature, and another 30 
sec at 72 °C with a reading taken at the end of this 30 sec. The 3rd step was to analyze the 
melting curve of the products. Therefore, the temperature increased from 65 °C up to 95 °C in 
1 °C increments. This increase occurred every 10 sec, and a reading was taken before each 
subsequent increase. All results were normalized based on average GAPDH levels of the 
Medium/PBS group within each trial.  
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Table 3.1 qPCR primer list 
List of qPCR primers used in this project. All sequences were made at Thermofisher, and PCR 
gradient was performed to check the sequences that were not already used within the lab. These 
sequences were Muc5A and Gob5. All other sequences were already optimized by previous lab 
members.  
 
    
Forward 5’ AACTTTGGCATTGTGGAAGG 3’ 
Reverse 5’ ACACATTGGGGGTAGGAACA 3’ 
Forward 5’ ACTGGGACGACATGGAG 3’
Reverse 5’ GTAGATGGGCACAGTGTGGG 3’ 
Forward 5' ATGTGGGCTTTGCTCTACCA 3'
Reverse 5' CCCCTCGGTTCCACACATAC 3'
Forward 5' TGTCCTGAGGGTATGGTGCT 3'
Reverse 5' ACCCGGTGCATAAAGTGTCC 3'
Forward 5' GAGCAGCACCTCCGAAGAACA 3'
Reverse 5' CCACAAACGATCCCCCTGAAGA 3'
Forward 5' GGAGATGGATGTGCCAAACG 3'
Reverse 5' ACCTTGGAAGCCCTACAGAC 3'
Forward 5' TCAAGTGGCATAGATGTGGAAGAA 3'
Reverse 5' TGGCTCTGCAGGATTTTCATG 3'
IL-4 78 bp 61.4
57.592 bpIFN-γ
Muc5AC 99 bp 55.4
61.4150 bpGob5
β-actin 266 bp 57.5
IDO-1 228 bp 57.5
GAPDH 223 bp 57.5
Target 
Gene
Direction Sequence
Amplico
n Size
Annealing 
Temperature (°C)
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3.6 FLOW cytometry procedure 
 
The BAL fluid cells were resuspended in cold Facola or PBS to aliquot a triplicate for 
each group, and to be pooled with other groups for the control wells. The lung tissue samples 
were resuspended in the same solutions at a concentration of 4 x107 cells/mL. 50 µL of these 
samples were dispensed into plates. The lung homogenates were separated into two plates based 
on if they were stained for neutrophils and eosinophils or stained for macrophages and DCs with 
subsequent internal staining for IDO-1. The BAL fluid cells were plated on a separate plate from 
the lung homogenates and only stained for neutrophils or eosinophils. The surface-staining 
procedure was the same for all plates, although PBS was used for the macrophages and DCs with 
the internal IDO-1 staining. 
All of the stained samples and controls (but not the un-stained controls) were blocked 
with TruStain fcXTM (anti-mouse CD16/32) Clone 93 from Biolegend, and incubated in the dark 
on ice for 5 min. Then 48 µL of the staining solution consisting of either Facola or PBS and 
designated conjugated antibodies (FITC, PE, APC, or eFluor 660) for each particular cell 
population (listed in Table 3.2) were added for staining. The un-stained controls received 50 µL 
of Facola or PBS to their wells. These plates were incubated under the same conditions for 30 
min and then centrifuged at 500 xg for 10 min. The supernatant was decanted from each well, 
and the cells were resuspended with 100 µL of their corresponding solution (the first wash). 
They were centrifuged at 500 xg for 5 min and resuspended in the same way a further 2 times as 
washes. After the third, and final wash, the wells with Facola were decanted, and the cells were 
resuspended in a fixing solution of Facola and 2% formaldehyde. The samples were shielded 
from light and stored at 4 °C to be analyzed within a week of processing.  
The plate with PBS was decanted, and the Cytofix/Cytomer Plus from BD Biosciences 
was used for internal staining of IDO-1 as instructed by the manual. The cells were resuspended 
in PBS at the end of the staining protocol and stored at 4 °C for reading. 
The samples were read with a BD FACSCalibur, and both gating and analysis were done 
using the Kaluza software. Initially, eosinophils were gated as CD11c- F4/80+, although there is 
evidence of subset macrophage populations that can also be identified this way. Besides, anti-Gr-
1 antibodies bind to both Ly6C and Ly6G. While Ly6G is only expressed on neutrophils, Ly6C 
is expressed on multiple immune cell types, including eosinophils. Therefore, to mitigate the 
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masking effect that neutrophils incur onto eosinophils seen within the data, the gating technique 
employed by Zaynagetdinov et al. (83) was used since the expression of Gr-1, and their side 
scattering (SSC), are distinct differences between these two cell populations. Thus, the 
neutrophils were gated as Gr-1high SSCint and the eosinophils as Gr-1int/low SSChigh.  
  
Figure 3.1 Gating for FLOW Cytometry 
Example of the gating procedure for 
eosinophils (CD11b+ Gr-1int/low SSChigh) and 
neutrophils (CD11b+ Gr-1high SSCint/low) of 
lung tissue. A similar gating procedure was 
done for BAL fluid. 
First live cells were gated from dead cells 
(gate A), second CD11b+ cells were gated 
(gate B), third the Gr-1- SSC- cells were 
excluded using the quadratic gates (gate C) 
and finally eosinophils were gated as Gr-
1int/low SSChigh (gate D) and neutrophils were 
gated as Gr-1high SSCint/low (gate E) and their 
percentages relative to total living cells was 
recorded. 
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Table 3.2 FLOW Cytometry cell marker list 
List of fluorescence-conjugated antibodies grouped by cell-type used within this project. 
  
Cell Type Cell Marker Isotype Clone Supplier
FITC anti-mouse/human CD11b Rat IgG2b, k M1/70
APC anti-mouse Ly-6G/Ly-6C (Gr-1) Rat IgG2b, k RB6-8C5
FITC anti-mouse CD11b
Armenian
Hamster IgG
N418
PE anti-mouse F4/80 Rat IgG2a, k BM8
eFluor® 660 IDO Rat IgG2b, k mIDO-48 Invitrogen
FITC anti-mouse CD11c
Armenian 
Hamster IgG
N418
PE anti-mouse I-A/I-E (MHCII) Rat IgG2b, k
M5/114.1
5.2
eFluor® 660 IDO Rat IgG2b, k mIDO-48 Invitrogen
Neutrophils/
Eosinophils
Biolegend
 Macrophage
Dendritic  
Cell
Biolegend
Biolegend
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3.7 Multiplex ELISA procedure for analysis of cytokine and chemokine profiles 
 
The lung homogenate and BAL fluid samples for Multiplex ELISA were defrosted, and 
the procedure within the instructor’s manual from Meso Scale Discovery was followed. The U-
Plex Custom Biomarker (ms) Assay and U-Plex T-Cell Combo kits were used for cytokine and 
chemokine detection. The Meso Scale Discovery software was used to measure the concentration 
of each protein. 
 
3.8 Total IgE titration 
 
The total IgE titration was done using the BD OptEIA Mouse IgE ELISA Set as per the 
instruction manual for blood, BAL fluid, and lung fragment cultures. A dilution of 1:2 was 
determined to provide the most accurate results, though both 1:2 and 1:5 dilutions were done in 
duplicate for each trial. The plates were read using the SPECTRA max 340PC and matching 
SOFTmaxPRO4.3.1 software. The software was used to calculate the standard curve, and Excel 
for the subsequent IgE titers for each of the samples. 
 
3.9 Statistical analysis 
 
GraphPad Prism 7 was used for statistical analysis of all results. One-way ANOVAs and 
Newman-Keuls methods were used to compare differences between multiple groups. Student t-
tests were used to compare individual groups if significance was found among the groups. 
Differences were considered significant if P < 0.05. As stated in Figure 3.1, all graphs are 
representative of three separate trials. All trials consisted of either 5 or 6 mice in each group. The 
dot plots represent individual mice within each group, and the error bars show median with 95% 
CI. The bar graphs are representative of pooled data within each group, and these error bars show 
the mean with SD.  
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4 RESULTS 
 
4.1 Developing an asthma model 
 
An asthma model was developed to determine how an underlying infection affects the 
response within the lung environment towards the CRA allergen. This model went through 
multiple iterations and improvements before obtaining adequate results. These iterations 
included a shift from the model based on a Kaiko et al. study to combining a model used by 
Whitehead et al. with one used by Lukas et al. This model provided an overall shorter timeline 
that revealed significant differences when compared to a negative group of mice, a second one 
that was only exposed to CRA and a third group that only had a PVM viral infection. 
 
4.1.1 The first model 
First, a model that was based on a Kaiko et al. study in 2013 (84) was previously 
initiated, and then improved on by myself. The model (Figure 4.1) was lengthy at 30 days long; 
30 pfu of PVM and 1 µg of CRA were used per mouse (combination group). Additionally, lung 
tissue mRNA (Figure 4.2) did not show any significant differences in the cytokines measured 
except for IFN-γ (Figure 4.2 A) when comparing the combination group with the CRA group 
and the negative control group. IL-4 mRNA did show a very small trending increase but was 
quite variable, and therefore no significance was identified (Figure 4.2 B). IDO-1 mRNA levels 
were also not different between the three groups (Figure 4.2 C).  
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Figure 4.1: First asthmatic model 
Schematic representation of the mouse model from a Kaiko et al. study (83). In the experiment there were three different groups of 
BALB/c mice aged 4-5 weeks: a negative control group (Medium/PBS), a CRA group (Medium/CRA), and a PVM/CRA group 
(combination). Mice were infected with 30 pfu of PVM in 50 µL of medium or 50 µL of medium without virus. Virus or medium 
was always administered intranasally on day 0. This was followed by intranasal inhalation of 1 µg of CRA allergen in 20 µL of 
PBS or 20 µL of PBS on day 3 p.i. A second and third inhalation of the same type was administered on day 10 and 17 p.i.; one 
week after the first and second exposure respectively. A fourth inhalation was administered on day 28 p.i. The first inhalation 
occurred two days before the viral infection had peaked, on day 5 p.i. (21). The lung environments were measured for changes in 
mRNA production of cytokines and IDO-1; Each finding shown is a representation of 1 trial, with 5 mice/group. 
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Figure 4.1: First asthmatic model 
Schematic representation of the mouse model from a Kaiko et al. study (83). In the 
experiment there were three different groups of BALB/c mice aged 4-5 weeks: a negative 
control group (Medium/PBS), a CRA group (Medium/CRA), and a PVM/CRA group 
(combination). Mice were infected with 30 pfu of PVM in 50 µL of medium or 50 µL of 
medium without virus. Virus or medium was always administered intranasally on day 0. This 
was followed by intranasal inhalation of 1 µg of CRA allergen in 20 µL of PBS or 20 µL of 
PBS on day 3. A second and third inhalation of the same type was administered on days 10 
and 17 respectively; one week after the first and second exposure. A fourth inhalation was 
administered on day 28. The first inhalation occurred two days before the viral infection had 
peaked, on day 5 (21). The lung environments were measured for changes in mRNA 
production of cytokines and IDO-1; Each finding shown is a representation of 1 trial, with 5 
mice/group. 
 
Figure 4.2 Cytokine and IDO-1 mRNA 
The mice were either inoculated with Medium or 30 pfu PVM and PBS or 1 µg of CRA. At 
day 30 p.i. lung tissue mRNA expression levels of select cytokines, and IDO-1 were 
observed. The lung tissue was flash-frozen in liquid nitrogen and stored at -80 °C for mRNA 
extraction. cDNA was produced and qPCR was performed. Both GAPDH and β-actin were 
used as housekeeping genes, but GAPDH has more stable mRNA basal levels. In each group, 
all 5 mice are shown as individuals. Each datum point corresponds to individual mice and the 
horizontal line represents the median with 95% CI. 
**** = P < 0.0001 
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4.1.2 Modification of this model 
Asthmatic symptoms are categorized as either early reactions or late reactions (85). 
Therefore, observations of symptoms 6 hours and 2 days after the last exposure would capture 
changes in the lung environment using the same combination group as used in the previous 
model (Figure 4.3). As can be seen in Figure 4.4 A IFN-γ mRNA is only significantly induced 
in the combination group on day 26 + 6 hrs p.i. There is too much variability within the day 28 
p.i. data to determine any significance. Figure 4.4 B shows the IL-4 mRNA expression, which 
did not show any significant differences between any of the three groups at either time-point. 
There is a trending increase in IDO-1 mRNA on Day 26 + 6 hrs p.i. that is also not significant at 
this time-point but became significant by day 28 p.i. (Figure 4.4 C). We also observed the 
mRNA production of mucosal proteins Muc5AC and Gob5. Figures 4.4 D & E show that 
neither of the mucous mRNAs was significantly induced in either the CRA group or the 
combination group. Finally, BAL fluid and lung tissue samples also did not show significant 
differences between the groups, although there were some trending differences within the BAL 
fluid at day 28 p.i. (Figure 4.4 F & G respectively). 
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Figure 4.3: Modified asthmatic model 
Schematic representation of a modified mouse model from a Kaiko et al. study (83). In the experiment there were three different 
groups of BALB/c mice aged 4-5 weeks: a negative control group (Medium/PBS), a CRA group (Medium/CRA), and a PVM/CRA 
group (combination). Mice were infected with 30 pfu of PVM in 50 µL of medium or 50 µL of medium without virus. Virus or 
medium was always administered intranasally on day 0. This was followed by intranasal inhalation of 1 µg of CRA allergen in 20 
µL of PBS or 20 µL of PBS on day 3 p.i. A second and third inhalation of the same type was administered on day 10 and 17 p.i.; 
one week after the first and second exposure respectively. A fourth inhalation was administered on day 26. The first inhalation 
occurred two days before the viral infection had peaked, on day 5 p.i. (21). The lung environments were measured for changes in 
mRNA production of cytokines and IDO-1; Each finding shown is a representation of 1 trial, with 5 mice/group. 
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Which legend 
  
Figure 4.4 Cytokine and IDO-1 mRNA, and cellular influx in BAL fluid and lung tissue 
The mice were either inoculated with Medium or 30 pfu PVM and PBS or 1 µg of CRA. (A – 
E) At day 28 p.i. lung tissue mRNA expression levels of select cytokines, and IDO-1 was 
observed. The lung tissue was flash-frozen in liquid nitrogen and stored at -80 °C for mRNA 
extraction. cDNA was produced and qPCR was performed. Both GAPDH and β-actin were 
used as housekeeping genes, but GAPDH has more stable mRNA basal levels. In each group, 
all 5 mice are shown as individuals. Each datum point corresponds to individual mice and the 
horizontal line represents the median with 95% CI. (F & G) BAL fluid and lung tissue cells 
were isolated on day 28 p.i. for the presence of eosinophils and neutrophils. Living cells were 
gated, and eosinophils were further gated as CD11b+ Gr-1int/low SSC
high; neutrophils were 
gated as CD11b+ Gr-1high SSCint/low. The percentage of eosinophils and neutrophils in the BAL 
fluid (F) and lung tissue (G) are shown. Each group consisted of 5 mice that were pooled and 
analyzed in triplicates.  Each bar represents the group as mean and the line represents the SD.  
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4.1.3 Final model 
Due to the lack of changes seen in the previous two models a combination of the 
Whitehead et al. and Lukacs et al. (74, 86, 87) models were altered to obtain a new 
infection/exposure protocol as shown in Figure 4.5. This protocol is much shorter in length and 
able to identify changes within the lung environment between a negative control group, a model 
with two CRA sensitizations (CRA group), and the same model with two CRA sensitizations and 
an underlying PVM infection during the first sensitization (combination group). 
In Figure 4.6 A the IFN-γ mRNA expression is increased in the combination group when 
compared to both the negative control and the CRA group. This result was similar to the same 
measurement in the last model, but the increased relative fold induction of this model was 
promising. IL-4 mRNA induction was also significantly increased in the CRA group (Figure 4.6 
B). Additionally, the combination group produced significantly more IL-4 mRNA when 
compared to the CRA group. Figure 4.6 C shows induction of IDO-1 mRNA within the 
combination group, but not in either of the other two groups. Finally, the mRNA induction of 
mucosal proteins Muc5AC (Figure 4.6D) and Gob5 (Figure 4.6 E) showed significant or 
trending increases within the CRA group compared to the negative control group, and significant 
increases in the combination group when compared to the CRA group.  
Additionally, there was a significant decrease of eosinophils within the BAL fluid of the 
combination group. The neutrophil population that increased within the BAL fluid of the CRA 
group was suppressed within the BAL fluid of the combination group (Figure 4.6 F). The lung 
tissue eosinophil and neutrophil populations were also significantly increased in the CRA group 
compared to the negative control group; the combination group showed enhanced significant 
increases of these populations compared to the CRA group (Figure 4.6 G). Finally, previous 
work establishing the virulence of the PVM strain defined that infection peaks at day 5 p.i. and is 
resolved by day 14 p.i. at a 30 pfu dose within Balb/c mice (Figure 4.7). Therefore, any 
differences in the lung environment of the combination group are towards CRA and not due to 
the remnants of the underlying PVM infection that ultimately effected how the lungs respond to 
CRA.  
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Figure 4.5 Schematic Representation of Mouse Model 
Schematic representation of the mouse model developed by combining a model used by 
Lukas (62) and one used by Whitehead (51). In each experiment there were three different 
groups of BALB/c mice aged 4-5 weeks: a negative control group (Medium/PBS), a CRA 
group (Medium/CRA), and either a PVM group (PVM/PBS) or a PVM/CRA group 
(combination). Mice were infected with 30 pfu of PVM in 50 µL of medium or 50 µL of 
medium without virus. Virus or medium was always administered intranasally on day 0. This 
was followed by intranasal inhalation of 50 µg of CRA allergen in 20 µL of PBS or 20 µL of 
PBS one week after infection on day 7 p.i. A second inhalation of the same type was 
administered on day 14 p.i.; one week after the first exposure. The first inhalation occurred 
two days after the viral infection had peaked, on day 5 p.i. (21), and the second inhalation was 
given on the day of viral clearance and one day before the mice were sacrificed. The lung 
environments were measured for changes in mRNA production of mucus proteins, cytokines 
and IDO-1; cellular influx of eosinophils, neutrophils, macrophages, and dendritic cells; and 
protein concentrations of cytokines. Each finding shown is a representation of 1 of 3 trials, 
with 6 mice/group. 
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Figure 4.6 Lung tissue mRNA, and cellular influx in BAL fluid and lung tissue 
The mice were either inoculated with Medium or 30 pfu PVM and PBS or 50 µg of CRA. (A 
– E) At day 15 p.i. lung tissue mRNA expression levels of select cytokines, mucin, and IDO-1 
was observed. The lung tissue was flash-frozen in liquid nitrogen and stored at -80 °C for 
mRNA extraction. cDNA was produced and qPCR was performed. Both GAPDH and β-actin 
were used as housekeeping genes, but GAPDH has more stable mRNA basal levels. In each 
group, all 6 mice are shown as individuals. Each datum point corresponds to individual mice 
and the horizontal line represents the median with 95% CI. (F & G) BAL fluid and lung tissue 
cells were isolated on day 15 p.i. for the presence of eosinophils and neutrophils. Living cells 
were gated; while eosinophils were as CD11b+ Gr-1int/low SSC
high, neutrophils were gated as 
CD11b+ Gr-1high SSCint/low. The percentage of eosinophils and neutrophils in the BAL fluid 
(F) and lung tissue (G). Each group consisted of 5 mice that were pooled and analyzed in 
triplicates.  Each bar represents the group as mean and the line represents the SD.  
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Figure 4.7 PVM-15 virus titration peak and clearance 
Balb/c mice were inoculated with 30 pfu of PVM-15 and sacrificed at days 5, 8, or 14 p.i. for 
viral titration assays. Individual lungs were weighed, homogenized, aliquoted, and flash 
frozen at minus 80°C. Samples were plated on pre-grown BHK-21 cells and incubated for 3 
days. Anti-PVM rabbit antibodies were applied to the wells after fixation and 
permeabilization; followed by alkaline phosphatase-conjugated goat anti-rabbit IgG; 
BIORAD substrate was used to identify virions. The plaques were numerated and titers as 
pfu/g were calculated. 
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4.2 Cockroach allergen and PVM infection inflict different long-lasting alterations to 
the lung environment 
 
In order to examine the lung environmental changes from either two CRA exposures or 
any long-lasting effects of a sub-lethal PVM viral infection, the mice were either infected with 
PVM or exposed to CRA. Three groups of mice were compared: the Medium/PBS group 
(control), CRA group (Medium/CRA), and PVM group (PVM/PBS). The changes in cytokine 
mRNA expression and protein production, as well as cell influx into the BAL fluid and lung 
tissue, were determined between the three groups. 
4.2.1 Gene expression within the lung tissue 
The lung tissue was homogenized within TRIZol solution to extract the mRNA produced 
and observe any differences between the three groups. As shown in Figure 4.8 A & B, the 
amounts of Gob5 and Muc5AC mRNA production of the CRA and PVM groups were equivalent 
at day 15 p.i. Gob5 only achieved a trending increase within the CRA group and the PVM group 
when compared to the Media/PBS group. While Muc5AC mRNA induction was significantly 
increased in both the CRA group and the PVM group as compared to the Media/PBS group, 
there was no difference found between the CRA group and the PVM group. The similarity in 
expression between the two groups indicated that CRA induced these two mRNAs to be 
produced, but the viral infection also induced mucosal mRNA production to occur even after 
viral clearance. Thus, the viral infection still affected mucus production even after it was cleared, 
and CRA induced mucosal mRNA production. This could be a possible memory response that 
lasted 24 hours after the encounter occurred. 
In addition, CRA did not induce an increase in IL-4 mRNA production with the 
exception of one mouse (Figure 4.8 C). None of the mice within the PVM group developed IL-4 
mRNA production. According to the research, there were no differences in IL-4 mRNA 
expression between the three groups. The lack of IL-4 mRNA production in response to the 
PVM infection was expected since PVM induces a Th-1 response rather than a Th-2 response 
(21, 22, 24). In contrast, the lack of IL-4 mRNA expression induced by the CRA was not 
expected since CRA is known to induce a Th-2 response (75). 
The expected increase in IFN-γ mRNA production (Figure 4.8 D) was observed in 
response to the residual PVM infection, but it did not occur after CRA inhalation.  
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IDO-1 mRNA was also measured as shown in Figure 4.8 E. It was found that CRA does 
not induce IDO-1 mRNA production 24 hours after stimulation, but it was still present after 
clearance of the viral infection. We have previously established that PVM does induce IDO-1 
mRNA during infection, and this mRNA seems to still be present after clearance. The induction 
of IDO-1mRNA within the PVM group suggests that it may be playing a role in resolving this 
viral infection.  
Within the overall results from the mRNA expression, it seems that CRA exposure may 
induce a similar mucosal response as PVM, but this would not be in a Th-2 mediated way, nor a 
Th-1 mediated way as the PVM infection had induced.  
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Figure 4.8 mRNA expression of cytokines and IDO-1 in the lung tissue 
The mice were either inoculated with Medium or 30 pfu PVM and PBS or 50 µg of CRA. At 
day 15 p.i. lung tissue mRNA expression levels of mucus proteins, select cytokines, and IDO-
1 was observed. The lung tissue was flash-frozen in liquid nitrogen and stored at -80 °C for 
mRNA extraction. cDNA was produced and qPCR was performed. Both GAPDH and β-actin 
were used as housekeeping genes, but GAPDH had more stable mRNA basal levels. In each 
group, all 5 mice are shown as individuals. Each datum point corresponds to individual mice 
and the horizontal line represents the median with 95% CI. 
* = P < 0.05 ** = P < 0.01  *** = P < 0.001 
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4.2.2 Cytokine and chemokine protein analysis 
Multiplex ELISA (Enzyme-Linked Immunosorbent Assay) was used to determine protein 
concentrations for a select number of cytokines and chemokines (Figure 4.9) within the BAL 
fluid of these three groups. We confirmed that IL-4 protein (Figure 4.9 A) was indeed present in 
the BAL fluid 24 hours after CRA exposure, but not seen after PVM clearance or within the 
Medium/PBS group. Significant amounts of IFN-γ protein (Figure 4.9 B) were also found in the 
BAL fluid of both the CRA and PVM groups compared to the Medium/PBS group. We did 
expect the PVM group to have residual IFN-γ proteins based on the mRNA data; thus, this 
continued presence after clearance is not too surprising. Unexpectedly, a similarly significant 
amount of IFN-γ protein was present within the BAL fluid after CRA inhalation. The relatively 
low amount of IFN-γ compared to IL-4 supports the conclusion that CRA induces a mixed, but 
dominantly Th-2, type of response. 
Interestingly, there was a small but significant increase of IL-10 protein (Figure 4.9 C) 
within the BAL fluid of the CRA group that was not observed in either the Medium/PBS group 
or the PVM group. This IL-10 is classically known to be secreted by T-reg cells, but there is also 
evidence of both Th-1 and Th-2 CD4+ T-cells secreting this cytokine after repeated exposure to 
an antigen (88, 89). 
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Figure 4.9 Protein profile of the BAL fluid 
The mice were either inoculated with Medium or 30 pfu PVM and PBS or 50 µg of CRA. 
Protein leve1s within the BAL fluid of each group at day 15 p.i. for select cytokines of Th-1 
(IFN-γ and sometimes IL-10) and Th-2 (IL-4 and sometimes IL-10) origin were measured 
with multiplex ELISA using the MSD kit and protocols. Each group consists of 5 mice and 
all are pooled and analyzed in triplicate. The data plots are shown as mean with SD.  
* = P < 0.05 ** = P < 0.01 **** = P < 0.0001 
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4.2.3 Lung tissue and BAL fluid cell efflux and influx 
After clearance of the virus and 24 hours after exposure to CRA, we investigated the 
BAL fluid and lungs for eosinophil and neutrophil presence. The BAL fluid within the PVM 
group contained a higher percentage of eosinophils (approximately 10% increase) and a lower 
percentage of neutrophils (~2%) compared to the CRA group and the Medium/PBS group 
(Figure 4.10 A).  Conversely, CRA induced an opposite effect within the BAL fluid compared to 
the PVM group and the Medium/PBS group. Neutrophils increased by about 35%, while 
eosinophils decreased by about 4-5% compared to the Medium/PBS group. Therefore, the 
suppression of eosinophil or neutrophil influx within the BAL fluid at the end of these trials 
shows that the lungs react to a CRA exposure differently than towards a PVM infection. The 
lung tissue cell influx (Figure 4.10 B) was also drastically different, but in other ways. The 
eosinophilic influx was reasonably stable between all three compared groups, but the neutrophils 
reacted differently between the CRA and PVM groups when compared to the Medium/PBS 
group. CRA induced a significant increase of about 5%, while the PVM infection suppressed 
neutrophilic influx by about 5%, below levels found in the Medium/PBS group. 
Therefore, the effects of PVM after viral clearance increased the eosinophilic influx 
within the BAL fluid while maintaining the regular proportion within the tissue. This 
eosinophilic increase is in conjunction with the suppression of neutrophils within both the BAL 
fluid and the lung tissue. In contrast, the CRA induction resulted in lower than average 
eosinophil, and higher than average neutrophil populations within the BAL fluid. Similarly, to 
the BAL fluid, the lung tissue contained an increased neutrophil population, while the 
eosinophilic population was maintained. Therefore, PVM promotes a high eosinophilic and low 
neutrophilic BAL, and low neutrophilic tissue environment. In contrast, CRA promotes a high 
neutrophilic, low eosinophilic BAL, and high neutrophilic tissue environment. These 
environmental differences within the lung tissue are indicative of the different immune responses 
induced by PVM (Th-1) and CRA (Th-2). 
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Figure 4.10 Cellular influx and efflux of neutrophils and eosinophils 
The mice were either inoculated with Medium or 30 pfu PVM and PBS or 50 µg of CRA. 
Lung tissue and BAL fluid cells were isolated on day 15 p.i. to detect the presence of 
eosinophils and neutrophils. Living cells were gated; while eosinophils were as CD11b+ Gr-
1int/low SSC
high, neutrophils were gated as CD11b+ Gr-1high SSCint/low. The percentage of 
eosinophils and neutrophils in the BAL fluid (A) and lung tissue (B). Each group consisted of 
5 mice that were pooled and analyzed in triplicates.  Each bar represents the group as mean 
and the line represents the SD. 
* = P < 0.05   *** = P < 0.001   **** = P < 0.0001 
 
 
62 
 
4.3 The lung environment is altered when an allergen is introduced during an acute 
viral infection 
 
The previous set of experiments showed the different responses that the lungs mounted 
towards either a set of CRA exposures or a sub-lethal PVM infection. The next step was to 
observe how the lungs would respond to a second CRA exposure when the first one occurred 
during the acute phase of a sub-lethal PVM infection. For this set of experiments, the 
Medium/PBS group (control), the CRA group (Medium/CRA), and the PVM/CRA group were 
tested to elucidate the type of response that would occur under these circumstances. 
 
4.3.1 Gene Expression Within the Lung Tissue 
The lung mRNA environment was extracted from the lung tissue 24 hours after CRA 
exposure with or without an underlying viral infection during the first exposure. As shown in 
Figure 4.11 A & B, while both of the CRA and PVM groups induced mRNA production of 
Gob5 and Muc5AC, the PVM/CRA group produced more Gob5 and Muc5AC mRNA than either 
of the CRA group or the Medium/PBS group. This increase could be a slight additive effect on 
the lung environment. Little to no IL-4 mRNA was produced by the CRA and PVM groups in 
Figure 4.8 C, though there was a trend of increase within the CRA group compared to the 
Media/PBS group. In these trials, both the PVM/CRA group and the CRA group (Figure 4.11 C) 
did show a significant increase in IL-4 mRNA production. This significant increase was in 
comparison to the Medium/PBS group, while the PVM/CRA group was additionally increased 
compared to the CRA group. The IFN-γ mRNA production (Figure 4.11 D) also was 
significantly increased within the PVM/CRA group compared to both the Medium/PBS group 
and the CRA group. Expectedly, there was no IFN-γ mRNA expression in the CRA group 
compared to the Medium/PBS group. Finally, the induction of IDO-1 mRNA (Figure 4.11 E) 
was only increased when there was a previous underlying PVM infection when compared to both 
the PVM/CRA group and the Medium/PBS group. The CRA group did not induce any 
differences in IDO-1 mRNA expression when compared to the Medium/PBS group.  
Therefore, the underlying previous PVM infection, and it is effects on the environment 
after clearance, leads to a different mRNA production profile towards CRA, and these 
differences are part of asthmatic development. 
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Figure 4.11 mRNA profile of the lung tissue within the thee groups 
The mice were either inoculated with Medium or 30 pfu PVM and PBS or 50 µg of CRA. At 
day 15 p.i. lung tissue mRNA expression levels of mucus proteins, select cytokines, and IDO-
1 was observed. The lung tissue was flash-frozen in liquid nitrogen and stored at -80 °C for 
mRNA extraction. cDNA was produced and qPCR was performed. Both GAPDH and β-actin 
were used as housekeeping genes, but GAPDH has more stable mRNA basal levels. In each 
group, all 5 mice are shown as individuals. Each datum point corresponds to individual mice 
and the horizontal line represents the median with 95% CI. 
 * = P < 0.05 ** = P < 0.01  *** = P < 0.001   **** = P < 0.0001 
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4.3.2 Cytokine and chemokine protein analysis 
The lung tissue was also homogenized and stored for cytokine analysis using a Multiplex 
ELISA kit from Meso Scale Delivery. Despite the PVM infection not inducing IL-4 protein 
production within the BAL fluid (Figure 4.9 A), there was a significant increase in this protein’s 
production in the PVM/CRA group. (Figure 4.12 A & B) This increase was significant in 
comparison to both the Medium/PBS group and the CRA group within the BAL fluid. This 
increase was seen in both BAL fluid and lung tissue of the PVM/CRA group compared to the 
Medium/PBS group. However, there was only a trending increase of IL-4 within the tissue of the 
PVM/CRA group compared to the CRA group. Therefore, the underlying PVM infection led to 
an increase in IL-4 production towards CRA.  
IFN-γ protein production within the BAL fluid was significantly increased towards CRA, 
and even more so when there was an underlying PVM infection (Figure 4.12 C & D). IFN-γ was 
increased within the PVM/CRA group despite PVM not inducing much IFN-γ on its own during 
the same time point (Figure 4.9 B). Even so, the lung tissue only determined an increase within 
IFN-γ proteins in the PVM/CRA group as compared to both the CRA group and the 
Medium/PBS group. There was no IFN-γ protein found within the CRA group or the 
Medium/PBS group. 
There was also a significant increase in IL-10 protein (Figure 4.12 E & F) in both BAL 
fluid and lung tissue when there was the underlying PVM infection as compared to the 
Medium/PBS group. This IL-10 was only seen within the PVM/CRA group compared to the 
CRA group. IL-10 protein was not found within the BAL fluid of the CRA group, although there 
was an increase in this protein found in the lung tissue compared to the Medium/PBS group. This 
increase was not significantly more induced in the PVM/CRA group’s lung tissue. 
IL-13 (Figure 4.12 G) was produced within the BAL fluid of the CRA group and was 
increased compared to the Medium/PBS group. The IL-13 within the BAL fluid of the 
PVM/CRA group was significantly increased compared to the Medium/PBS group, but it only 
showed a trending increase when compared to the CRA group. This IL-13 production further 
indicated that CRA induced a Th-2 response. Additionally, the Th-2 response became more 
balanced when the first CRA exposure occurred during a PVM infection. 
Therefore, based on the protein analysis, it can be concluded that the response towards 
CRA is altered from an overall high IL-4 induction to a mixed IL-4 and IFN-γ production, while 
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also producing IL-10 and IL-13. Except for IL-13, this combination of proteins was seen in both 
tissue and BAL fluid samples, but the BAL fluid supported a Th-1 induction while the lung 
tissue produced a Th-2 response. 
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Figure 4.12 Protein profile of the BAL fluid and the lung tissue of the groups 
The mice were either inoculated with Medium or 30 pfu PVM and PBS or 50 µg of CRA. 
Protein leve1s for select cytokines of Th-1 and Th-2 origin within both the BAL fluid (A, C, 
E, and G) and the lung homogenate samples (B, D, and F) from day 15 p.i. All samples were 
measured with multiplex ELISA using the MSD kit and protocols. Each group (Medium/PBS, 
CRA group, and PVM/CRA group) consisted of 6 mice. Each datum point correspond to 
individual mice and the horizontal line represents the median with 95% CI. 
* = P < 0.05   ** = P < 0.01   *** = P < 0.001   **** = P < 0.0001 
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4.3.3 Total IgE concentrations 
Both BAL fluid and LFC supernatants were stored and analyzed with an IgE ELISA kit 
to observe whether there were any changes in the IgE titers between the three groups. IgE was 
not induced by CRA exposure alone within the BAL fluid and the lung tissue. Thus, an 
underlying PVM infection was necessary for this induction (Figure 4.13 A & B). IgE titers 
increased within both BAL fluid and the lung tissue samples of the PVM/CRA group when 
compared to both the Medium/PBS group and the CRA group. This lack of increase in IgE titer 
within the CRA group was unexpected since CRA has been reported to increase both total and 
CRA-specific IgE titers (75). Therefore, there was a change in how IgE induction occurs when 
the mice are exposed to CRA during an underlying PVM infection. The exacerbated Th-2 
response shown through the mRNA expression and protein production suggests that there could 
be a necessary threshold to induce IgE production. 
 
 
 
 
 
  
Figure 4.13 Total IgE titers in LFC and BAL fluid samples 
The mice were either inoculated with Medium or 30 pfu PVM and PBS or 50 µg of CRA. IgE 
titers in BAL fluid (A) and lung fragment cultures (B) collected at day 15 p.i. measured by a 
sandwich-ELSA from BD Biosciences. Each group (Medium/PBS, CRA group, and 
PVM/CRA group) consisted of 6 mice. Each datum point corresponds to an individual mouse 
and the horizontal line represents the median with 95% CI. 
* = P < 0.05 
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4.3.4 Lung tissue and BAL fluid cell efflux and influx 
The presence of eosinophils and neutrophils was observed within the lung tissue and the 
BAL fluid using FLOW Cytometry. Additionally, macrophages and DCs and their expression of 
IDO-1 protein were also measured using this method. The cellular influx within the lungs of the 
PVM/CRA group was also different from the response towards each treatment on its own. In the 
BAL fluid (Figure 4.14 A), the eosinophils were similarly suppressed in the CRA group and the 
PVM/CRA group, in contrast to the massive eosinophil influx found within the PVM group 
(Figure 4.10 A). In spite of this similar eosinophil proportion, the high neutrophil influx to the 
BAL fluid in the CRA group was also reduced back to almost normal levels in the PVM/CRA 
group. Therefore, the high neutrophilic and low eosinophilic levels within the BAL fluid towards 
CRA has been altered to be low eosinophilic with no changes in neutrophilic influx when there 
was an underlying PVM infection. This cellular influx combination was also different from the 
high eosinophilic low neutrophilic BAL fluid found within the PVM group (Figure 4.10 A). 
The lung tissues (Figure 4.14 B) showed a small, but significant, increase in eosinophil 
and neutrophil influx within the CRA group and the PVM/CRA group compared to the 
Medium/CRA group. However, there was no difference in either the eosinophil or neutrophil 
influx between the PVM/CRA group and the CRA group.  
Correspondingly, there was an overall increase in total macrophage and DC populations 
within the PVM/CRA group’s lung tissue compared to the Medium/PBS group (Figure 4.14 C 
& D). Although there was no difference in the macrophage populations between the PVM/CRA 
group and the CRA group, the number of DCs were different between these groups. 
Additionally, there was an increase of IDO-1+ macrophages and DCs within the PVM/CRA 
group compared to both the Medium/PBS group and the CRA group. Increased IDO-1+ 
macrophage and DC populations within the CRA group were also found when compared to the 
Medium/PBS group. The IDO-1 mean fluorescent index (MFI) within the macrophage 
populations was significantly increased in the PVM/CRA group and the CRA group when 
compared to the Medium/PBS group (Figure 4.14 E).  However, there was no difference in the 
macrophage population between the CRA group and the PVM/CRA group. The IDO-1 MFI was 
also significantly increased within the DCs when comparing the PVM/CRA group to the CRA 
and Medium/PBS groups. The CRA group also had a significant increase of IDO-1+ DCs 
compared to the Medium/PBS group, but the PVM/CRA group was further increased. Therefore, 
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the underlying PVM infection within the PVM/CRA group did significantly change the lung 
environment and cellular influx when compared to the Medium/PBS and CRA groups.   
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  Figure 4.14 BAL fluid and lung tissue cellular influx and efflux 
The mice were either inoculated with Medium or 30 pfu PVM and PBS or 50 µg of CRA and 
their lung tissue and BAL fluid sampled at day 15 p.i. Percentage of cell populations in the 
BAL fluid (A) and lung tissue (B – E). FLOW cytometry was performed and gating was as 
follows: living cells were gated based on FSC and SSC. Eosinophils are CD11b+ Gr-1low/int 
SSC high, neutrophils are CD11b+ Gr-1high SSClow/int, macrophages are gated as CD11b+ 
F4/80+, finally DCs are gated as CD11c+ MHCII+. Additionally, macrophages and DCs were 
gated as either being IDO-1+ or IDO-1- and the MFI was measured using the geometric mean 
of the IDO-1 axis. Each group consisted of 6 mice that were pooled and tested in triplicate. 
The data is represented as mean with SD.   
* = P < 0.05   ** = P < 0.01   *** = P < 0.001   **** = P < 0.0001 
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5 DISCUSSION AND CONCLUSION 
 
5.1 RSV infection and allergen exposure 
 
Both RSV and PVM are known to be associated with eosinophil influx during infection 
(90). This association has always been shown as a negative function of the immune response, but 
it could be assisting in viral clearance (90, 91). The data has shown that after viral clearance 
within the PVM group, there is still a high eosinophil influx within the lungs of these mice. This 
influx can be indicative of viral clearance since the virus is cleared by day 14 p.i. Also, the 
cellular response of the CRA group is neutrophilic with eosinophilic efflux suggesting the 
eosinophils are not necessary for CRA clearance. The dampening of the eosinophil influx from 
the viral response after two CRA introductions is primarily a response induced by CRA since 
this suppression was also seen in the CRA group when compared to the Medium/PBS group. 
Therefore, it is a product of how the response is shifting from antiviral to anti-CRA. I have 
confirmed that viral clearance still occurs by day 15 p.i. and therefore is not delayed due to CRA 
introduction. In addition, the level of cell influx is reasonably equivalent between the PVM/CRA 
and the CRA group. Therefore, this suggests that suppression or dampening of eosinophil influx 
is due to the introduction of CRA within the lungs, and not modified by the viral infection that 
has been cleared by day 15 p.i. 
The mRNA expression of mucus glycoproteins, Muc5AC and Gob5, seems to have a 
synergistic induction. The high level of mucus mRNA still found at day 15 p.i. was similar 
within the PVM and CRA groups. When CRA was introduced into an environment where mucus 
production was still quite high, it induced even more mRNA production. RSV is also able to 
induce mucus production, (92) and mucus production seems to be governed by many factors, 
including IL-13. It is well known that CRA induces IL-13 secretion, so it is not surprising to find 
mucosal mRNA induction. PVM also induces IL-13 within the BAL fluid as seen in the Kaiko et 
al. paper (84).  
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Many researchers have shown that CRA induces IL-4 protein production, but only one of 
them has also looked at IFN-γ production (75). Within this model, CRA did induce low levels of 
IFN-γ protein production within the BAL fluid, although it was at similar levels to those induced 
by the PVM group after viral clearance. IFN-γ protein significantly increased within the BAL 
fluid and the lung tissue when CRA was administered to mice with an underlying PVM 
infection, but there was not as much of an increase within the tissue samples. The lung 
environment induced by PVM lead to a significantly higher IFN-γ production than that promoted 
by the CRA group and the Medium/PBS group. This amount was overall lower within the BAL 
fluid. Therefore, the cells producing IFN-γ were re-stimulated when CRA was introduced; 
alternatively, the stimulation could be an enhancement of the continued sequela from the viral 
response. Since the first CRA exposure in the model used here was during acute viral infection, 
and not before infection or after it has been cleared, the immune system may have had some 
additional responses towards CRA that are not usually seen.  
Neither IDO-1 enzymatic activity nor induction of IDO-1 protein has been investigated 
within CRA asthma models. One study evaluated IDO-1 activity within human DCs sensitized to 
HDM allergen (93). In this study, the IDO-1 activity and its metabolites (3HAA and KYN) seem 
to give previously sensitized DCs a Th-2 skewed response with little to no IFN-γ production. The 
Th-2 skewed response was prominent in the lung tissue while the BAL fluid showed a more 
mixed Th-1/Th-2 response. These differences are more than likely due to the fact that HDM 
probably elicits a different outcome than CRA when it enters the lung environment. 
In contrast, CRA did not induce IDO-1 mRNA production. However, there was an 
overall increase in IDO-1+ macrophages and DCs and amount of IDO-1 within each cell of these 
populations. The PVM infection did significantly induce this mRNA, and also showed increased 
IFN-γ mRNA expression. Therefore, the increased IDO-1 mRNA could have been due to the 
IFN-γ mRNA expression. The increase in IDO-1 protein found within the macrophages and the 
DCs could be due to the significant IFN-γ protein found within the CRA group even though there 
was no IFN-γ mRNA being expressed by this point. Alternatively, the macrophages and DCs 
within the lung tissue were being restimulated by CRA regardless of a previous underlying PVM 
infection, and that stimulation had induced more overall IDO-1 mRNA that was already 
degraded by day 15 p.i. Alternatively, because more IDO-1 protein was found within each cell, 
the increased protein amount could also be due to a lack of IDO-1 degradation within these cells. 
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Therefore, IDO-1 activity is a new function of PVM/CRA induced asthma. The introduction of 
CRA during a viral infection, where IDO-1 production is already induced, promotes a response 
that includes more IDO-1 mRNA expression and protein production instead of just a sustained 
increase of IDO-1 protein production.  
 
5.2 Understanding the implications of allergen exposure during early-childhood 
 
While there was a study done by the Lukacs lab (18) that suggests CRA induces an 
eosinophilic response, this model is different compared to my model. This model consisted of 
daily intranasal exposures to 1 µg of CRA for 7 days (days 0-6), after an RSV infection, instead 
of PVM. The mice were infected either 21 days before (day -21), on the day of (day 0), or 21 
days after the first CRA exposure (day 21). This continual introduction of CRA would have 
stimulated a different response due to the much smaller amount of CRA used, and the constant 
restimulation of the lungs. Also, 35 days after the first CRA exposure, the mice were re-exposed 
to 1 µg of  CRA intranasally and then exposed to 4 µg of CRA intratracheally on days 40 and 42. 
Although this model also replicates how the exposure timeline may occur within a child that 
could develop asthmatic responses, this is not the only timeline of exposure a child could go 
through. These different observations within different models can emulate the variation in 
asthma development and manifestation. 
A second study was done by the same group that did show a polymorphonuclear cellular 
influx (commonly known as neutrophils) due to CRA introduction (79). These two studies 
differed in their CRA exposure timeline, the number of exposures, and the exposure method. 
This neutrophilic influx does not change whether RSV was administered beforehand. CRA did 
induce quite a large influx of neutrophils within the BAL. This study also confirmed that more 
neutrophils influx to the BAL than do eosinophils. My model’s neutrophilic influx was slightly 
dampened when PVM was first administered; the timing of viral and CRA administration could 
account for the difference in neutrophil response. 
Similarly, a model with only CRA induction also showed a high neutrophilic influx, with 
the induction of IL-5, IL-13, and IL-10 (75). Their model was somewhat intense with intranasal 
exposures of 120 µg of CRA twice a week, one day apart, for three weeks (days 3, 5, 10, 12, 17, 
and 19 p.i.). The mice were sacrificed 4 days after the last CRA treatment. Therefore, their 
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results represented the late or chronic response towards CRA, while mine represented more of 
the early responses induced by CRA. Hence, a more chronic response towards significant CRA 
exposure coincides with the constant neutrophilic influx and a gradual increase of IFN-γ protein 
secretion along with Th-2 cytokine secretions. This cellular influx is difficult to explain in 
context with the cytokine profile, since neutrophils are considered part of the Th-17 response, 
(20) while eosinophils are considered part of the Th-2 response. Even so, neutrophils are known 
to have a protective phenotype as well, which is a potential reason for this seemingly 
inappropriate combination of responses. Again, this model showed nominal eosinophilic influx, 
whereas mine showed suppression, but that could be either the intensity of the exposures or the 
delayed time between the last exposure and the sampling day. Since neutrophilic influx is 
maintained for 24 hrs and up to 4 days after CRA induction, this is a noteworthy part of why 
CRA on its own seems to be such an essential factor in asthma induction.  
There are still some commonalities between the previously reported models and the one 
used here. Those include a higher induction of IL-4 and some induction of IL-13. CRA can 
induce an eosinophilic influx after multiple closely spaced exposures, though it promotes a more 
neutrophilic influx after a few introductions spaced over a more extended period. There is still 
high IL-4, and IL-13 induction regardless of how the mice are exposed to the CRA allergen. 
Therefore, CRA does seem to induce a traditional Th-2 cytokine environment. The implication 
of a viral infection is still quite complex; I feel it is based on the timing of compounding factors 
as much as it is based on the type of viral infection or allergen combination used. 
 
5.3 General conclusion and future directions 
 
A future direction would be to perform an extended trial where this second CRA 
exposure, or even a third one, occurs after viral clearance and when the environment has returned 
to normal levels. This way, the CRA exposure would be based on memory response and not also 
on the lasting effects of viral infection after clearance. Also, another sacrificial time-point at day 
8 would be beneficial to observe the initial immune response towards the antigen during 
infection, while also confirming that there are still viable virions within the lungs after this 
exposure. Another future direction would be to elucidate the effects of IDO-1 enzymatic activity 
on this model. The signalling activity would be vital to elucidate as well, though that could be 
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compensated through IDO-2 signalling function. Therefore, an IDO-2KO and IDO-1 enzymatic 
mutation (or adding 1-MT to the drinking water) would be ideal variables to investigate. 
Although increasing the amount of CRA and PVM given to the mice could be modified in the 
future, a combination of 50 pfu PVM-15 and 100 µg CRA was attempted. This combination 
could not be replicated due to the unhealthy condition of mice during this trial. 
Another thought is differentiating the types of neutrophils that are entering the BAL fluid 
because it is known that neutrophils are either protective or pathological depending on the 
cytokine environment (94). IL-33 secretion within the liver environment produced 
immunosuppressive neutrophils during an LCMV infection. According to Liang et al., this was 
due to ILC2 cells that are potently stimulated by IL-33 and start producing IL-13 (94). This IL-
13 then induced neutrophils to produce arginase (Arg)-1, which is an enzyme that breaks down 
arginine. This break-down of arginine led to the stunted proliferation of CD8+ T-cells. Therefore, 
more studies need to be done on the asthmatic neutrophil influx and how it may be an ‘over-
protective’ response, which may lead to different aspects of tissue injury.  
In conclusion, the mouse model used here is indicative of another way asthma 
development may occur. This model also showed how exposure after the acute respiratory 
infection was able to modify the natural CRA response that showed a dampening of the long-
lasting neutrophilic response, while promoting a more traditional Th-2 response, without the 
addition of eosinophil influx. This response was stronger than what was induced in the CRA 
group.  
More work needs to be done in the early stages of response development, such as on day 
8 of this model. The changes in memory response towards CRA seen on day 15 p.i. within the 
PVM/CRA group compared to the CRA group suggests that there is an alteration of the cytokine 
profile and cell populations within the lungs. This alteration would happen as a result of CRA 
being administered on day 7 post PVM infection. Therefore, sampling on day 8 of the PVM 
infection (24 hours after the first CRA exposure) could ideally show whether the initial response 
towards CRA is altered due to the underlying PVM infection. In this way, it may be possible to 
determine how the mixing of signals could develop different combinations of memory responses 
towards what should be a benign particle. 
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